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ABSTRACT 
Tuberculosis (TB) is a major health problem, especially in Africa and Southeast Asia. 
The disease, caused by Mycobacterium tuberculosis, (Mtb) is curable with a multidrug 
regimen of Rifampicin (RIF), Isoniazid (INH), Ethambutol and Pyrazinamide. However, 
treatment is not always successful, as ~ 2 million patients fail treatment each year, in 
part, because the bacterium has become resistant to these drugs.  Thus, efficient 
diagnosis of drug-resistant Mtb is extremely important. This study sought to determine if 
a new molecular assay, the Genotype MTBDRplus, could accurately detect drug-
resistant Mtb in Cameroon.  When compared to the conventional drug susceptibility 
testing assay, the molecular assay identified 98% (48/49) RIF-resistant isolates, 92% 
(55/60) INH-resistant isolates, and 94% (46/49) of Mtb resistant to both drugs in 
Cameroonian TB patients. Further evaluation of the molecular assay with an additional 
50 Mtb isolates, identified 6% (16/275) of isolates with questionable RIF-resistant 
results.  To determine if these 16 isolates were truly RIF-resistant, the Rifampicin 
Resistance-determining Region of the rpoB gene were sequenced. Mutations were 
found known as ‘disputed’ RIF mutations, i.e., mutations that are not always associated 
with resistance to RIF. Thus, sequencing results confirm that when DNA from Mtb 
isolates do not hybridize with the wild-type rpoB probe, it is wise to assume the Mtb 
isolate is RIF-resistant and treat accordingly. The Genotype MTBDRplus assay can be 
adopted by the government of Cameroon to diagnose drug-resistant TB.  In addition to 
mycobacterial mutations, host factors that cause sub-therapeutic plasma drug 
concentration could lead to treatment failure. One of such host factors could be variation 
in the liver efflux pump, P-glycoprotein (p-gp). Therefore, the relative amount of p-gp 
V 
protein in 87 human liver samples was measured. P-gp was found to be present from 
birth reaching 90 % of adult levels by age 5. Since low variability (2.9 + 0.32 fold) in p-
gp occurred among individuals, it is unlikely variability in p-gp protein accounts for wide 
variation in RIF plasma levels. The data are important because expression p-gp in 
children provides a plausible explanation as to why, when given the same dose/kg of 
RIF as adults, children clear the drug faster.  
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CHAPTER 1 
INTRODUCTION 
1.1 Global Burden of Tuberculosis 
Tuberculosis (TB) is currently the world’s most common cause of death from an 
infectious disease, including HIV and malaria. According to the World Health 
Organization (WHO), in 2015, 10.4 million people developed active TB disease, of 
whom, 1.8 million people died (1). TB is caused by the bacterium Mycobacterium 
tuberculosis (Mtb). Mtb predominantly affects the lungs causing active pulmonary TB 
disease but could also affect any part of the body causing extrapulmonary TB disease 
(2). 
Exposure to Mtb may cause either active disease or latent TB. People become 
exposed when they inhale aerosolized droplets generated by a patient with pulmonary 
TB, e.g., when they cough, sing, or shout. As shown in Fig 1, exposure to Mtb does not 
always lead to infection, because only 
30% of those exposed become 
infected. Among those infected, 5 -
10% will develop active TB disease 
within two years of exposure, while 
the remaining 90-95% of infected 
individuals will develop latent TB. 
Latent TB is defined as having 
evidence of Mtb infection by a positive 
reaction to Mtb antigens in a 
Fig.1. Spectrum of exposure to TB: from 
exposure to active disease or latent infection 
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tuberculin skin test (TST), but no clinical signs of disease and a negative chest 
radiograph. About 2 billion people in the world are infected with latent TB and 5-10% of 
these latently infected individuals will develop active TB disease (reactivation TB) during 
their lifetime (1–3). 
1.2 Treatment of Tuberculosis  
TB is a treatable disease. Patients with active TB disease are treated with a 6-
month regimen of combined therapy composed of the four drugs: Rifampicin (RIF), 
Isoniazid (INH), Pyrazinamide (PZA), and Ethambutol (EMB). All four drugs are 
administered during the first 2-months but for the remaining 4 months, only RIF and INH 
are administered (4). To ensure that patients comply with the lengthy duration of 
treatment, pharmacotherapy is usually administered through the Directly Observed 
Treatment and Short-course drug therapy (DOTS) program. In the DOTS program, the 
health worker or community volunteer provides the drugs to the patient and observes as 
the patient takes the drugs (5). A TB patient is classified “treatment success” if sputum 
from the patient is smear- or culture-negative during the last month of treatment and the 
person ingested the drugs for the entire 6-month program without any evidence of 
treatment being interrupted (6).  
1.3 Factors that increase the risk of treatment failure in TB patients 
Treatment of TB patients with the standard 6-month drug regimen of RIF, INH, 
PZA and EMB is expected to lead to treatment success in all patients who adhere to the 
regimen (7). Unfortunately, about 12 - 20% of TB patients fail treatment and another 3 – 
10% relapse within 2 years of completing their medication regimen, despite having 
drug-susceptible Mtb (1,8,9). Treatment failure is due to two major factors: (i) microbial 
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and (ii) host factors. As shown in Fig 2, patients harboring persistent or drug-resistant 
Mtb are likely to fail treatment (10–14). Likewise, patients with an impaired or 
compromised immune response or with inadequate plasma anti-TB drug levels are also 
likely to fail treatment (15,16). 
 
 
 
 
 
 
Fig 2: Microbial and Host factors that increase risk of TB treatment failure 
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1.4 Microbial factors that increase risk of treatment failure in TB patients 
1.4.1 Drug-persistent Mycobacterium tuberculosis 
Microbial drug-persistence is a phenomenon whereby some bacterial cells within 
a population survive the effects of antimicrobial treatment without acquiring resistance-
conferring genetic changes. These surviving bacterial cells are called drug-persistent 
microbes. Drug-persistent microbes are genetically identical to drug-susceptible 
microbes and appear to be either slow-growing or non-replicating in the presence of the 
drug but resume growth once the drug dissipates. Unlike drug-resistant microbes, drug-
persistent microbes have nonheritable phenotypic resistance to antimicrobial drugs and 
their progenies remain fully drug-susceptible to antimicrobials upon regrowth (11,17–
19). To date, all bacterial species including Mtb have been reported to produce drug-
persistent microbes (20).  
When exposed to Mtb bacilli, most anti-TB drugs demonstrate a biphasic killing 
activity. Effectively, the fast growing bacilli (that are one Mtb subpopulation), are rapidly 
killed while another subpopulation, the slowly or non-replicating bacilli, respond more 
slowly to the anti-TB drugs. This biphasic killing indicates that there are at least two Mtb 
subpopulations and these subpopulations differ in their intrinsic drug susceptibility 
(10,20–26). The slowly or non-replicating subpopulation are drug-tolerant and referred 
to as drug-persistent Mtb bacilli (22).  
Mtb bacilli can become drug-persistent through several mechanisms. These 
mechanisms include: expression of toxin-antitoxin modules that suppress metabolic 
activities (27); asymmetric growth of bacilli during cell division producing physiologically 
distinct daughter bacilli with differential susceptibility to antimicrobials (28); stochastic 
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expression of drug activating genes, such as no or reduced expression of catalase-
peroxidase KatG enzyme that activates INH into its active form (29); and up-regulation 
of efflux pumps, such as the efflux pump Rv1258 to inhibit cellular accumulation of RIF 
(12). The formation of drug-persistent bacilli following exposure to the anti-TB drug 
could be viewed as an adaptation of a subpopulation of Mtb bacilli to resist the adverse 
effect of the drugs. These drug-persistent Mtb bacilli can impair treatment, resulting in 
treatment failure or relapse but more disturbingly, they could eventually evolve to drug-
resistant Mtb bacilli (30,31).  
1.4.2 Drug-resistant Mycobacterium tuberculosis 
According to MacGowan (2008), drug resistance in pathogenic bacteria can be 
defined in two ways: first, in terms of the clinical outcome that is a patient receives the 
drug and is not cured and secondly with reference to the drug-susceptibility of the 
bacterial population prior to treatment. As clinical outcome cannot be determined prior 
to treatment, drug-resistance is generally defined based on drug-susceptibility of the 
bacterial population prior to treatment (32). Drug-resistant TB is also defined based on 
the drug-susceptibility of the Mtb population prior to treatment (33). As a consequence, 
a patient with drug resistant-TB is a patient who harbors Mtb bacilli that are resistant to 
the drug concerned and the patient will fail to respond to treatment with the drug (33). 
Globally, drug-resistant TB has been an area of growing concern and poses a 
dire threat to the effective control of TB (1,34,35). This threat is exemplified by the 
outbreak of drug-resistant TB in New York City in the early 1990s (36), with nearly all 
major hospitals reporting drug resistant TB cases and fatality rates greater than 80% 
(37). Today, fewer than 20 cases of drug-resistant TB (38) are reported in New York 
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City each year, but high numbers of cases are still reported in other parts of the world 
where drug-resistant TB is on the rise (1). Drug-resistant TB can be acquired in two 
ways: (i) during TB treatment owing to poor dosing or patient non-adherence to 
treatment or (ii) following contact with a drug-resistant TB patient. The former accounts 
for more drug-resistant TB cases than the latter (1,34). 
There are several types of drug-resistant TB (Table 1), but the most prevalent is 
multidrug-resistant TB (MDR-TB). MDR-TB is defined as Mtb with in vitro resistance to 
both RIF and INH. According to the WHO, in 2015, an estimated 480,000 new cases of 
MDR-TB occurred. About 21% of previously treated TB cases developed MDR-TB, 
while 3.9% of new TB patients had MDR-TB. Still, in the same year, 250,000 patients 
with MDR-TB died. More disturbing is the tendency of MDR-TB patients to progress to 
more severe forms of drug-resistance such as extensively drug-resistance TB (XDR-
TB). XDR-TB is Mtb with in-vitro resistance to at least RIF, INH, a quinolone, and 1 of 3 
second-line injectables agents. Globally, about 9.5% of MDR-TB cases have XDR-TB 
(1,34). 
Table 1: Different types of drug-resistant tuberculosis* 
 Form of drug-resistant 
TB 
Definition 
1 Mono-drug-resistant 
TB 
Mtb with in-vitro resistance to one of the drugs used for the 
treatment of drug-susceptible TB. Drug-susceptible TB is 
treated with RIF+INH+PZA+EMB 
2 Poly-drug-resistant TB Mtb with in-vitro resistance to more than one of the drugs 
used for the treatment of drug-susceptible TB other than 
both RIF and INH. 
3 Multidrug-resistant TB 
(MDR-TB) 
Mtb with in-vitro resistance to at least RIF and INH 
4 Pre-extensively drug-
resistant TB (Pre-XDR 
TB) 
Mtb with in-vitro resistance to at least RIF and INH and 
either a fluoroquinolone or 1 of 3 second-line injectables 
agents (amikacin, kanamycin or capreomycin) but not both.  
5 Extensively drug-
resistant TB (XDR-
Mtb with in-vitro resistance to at least RIF, INH a quinolone, 
and 1 of 3 second-line injectables agents  
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TB) 
6 Totally drug-resistant 
TB or extremely drug-
resistant TB (XXDR 
TB) 
Mtb with in-vitro resistance to all drugs used to treat drug-
susceptible TB as well as all drugs used to treat at least 
RIF, INH a quinolone, and 1 of 3 second-line injectables 
agents 
Definitions obtained and modified from (39) 
 
As the incidence of drug-resistant TB increases, new types of drug-resistant TB 
emerge. If nothing is done to combat the increasing number of drug-resistant TB cases, 
it will lead to the emergence of a group of patients for whom there are no drugs 
available. Although there is hope that new drugs will be quickly discovered, preventive 
methods, such as early and rapid detection of patients at risk of developing drug 
resistance, could be used to reduce the spread of drug-resistant TB. Early and rapid 
drug susceptibility testing of patients will lead to the immediate initiation of appropriate 
treatment of patients thereby limiting spread (40). 
 
1.4.3 Diagnosing Drug-resistant Tuberculosis 
As previously defined, drug-resistant TB refers to Mtb isolates with in vitro 
resistance to the drug being tested. As such, diagnosing drug-resistant TB implies 
conducting drug susceptibility testing (DST) of Mtb isolates to the various drugs. Several 
assays are available for the DST of Mtb isolates. These assays could be classified as 
either phenotypic or genotypic.  
 
1.4.3.1 Phenotypic assays for diagnosing drug-resistant TB 
Prior to 1960, diagnostic laboratories used diverse phenotypic or culture-based 
assays for DST of Mtb isolates. Although the underlying principles were the same, the 
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assays used different methods to categorize Mtb isolates as either drug-resistant or 
drug-sensitive. The three methods used were the absolute concentration method, the 
resistance-ratio method, and the proportion method. Following a consensus meeting 
organized by WHO in 1961, the culture-based proportion method was adopted as the 
standard method for DST of Mtb isolates (33,41).  
In the culture-based proportion method, a clinical specimen from a patient is 
cultured in a solid or liquid medium for growth of Mtb (33,41). Once growth of Mtb is 
observed, a suspension of the bacteria is made and adjusted to a turbidity equivalent to 
that of a 0.5 McFarland standard units and used for DST (33,41). To perform DST, two 
slants or tubes are used. One slant or tube contains only medium and is referred to as 
the drug-free slant or tube, while the other slant or tube contains both medium and a 
single concentration of the drug being tested. This single concentration is referred to as 
the critical concentration (33,41). A 1:100 dilution of the growth suspension is made and 
added to the drug-free slant or tube, while the undiluted growth suspension is added to 
the drug-containing slant or tube. Either slants or tubes are incubated and checked for 
growth of Mtb bacilli. Once growth is observed, the numbers of colonies on the drug-
free and drug-containing slants or tubes are counted (33,41). According to the 
proportion method, the Mtb isolate is classified as resistant to the drug if the number of 
colonies on the drug-containing medium is ≥ 1 % of the colonies on the drug-free slant 
plate (33,41). The underlying assumption in this method is that drug resistance 
develops by natural selection even without exposure to the drug. As such every Mtb 
isolate will be heterogeneous consisting of both drug-resistant and drug-susceptible 
bacilli. Hence, for a susceptible Mtb isolate, the proportion of potentially resistant bacilli 
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based on the mutation rate of 1 in 100 million cells would theoretically be only 
0.000001% of the entire population (33,41). Thus, the presence of 1% resistant bacilli 
represents a substantial increase in resistance. This assumption further implies that the 
difference between a resistant and susceptible Mtb isolate is that the former has a 
larger proportion of resistant bacilli, comprising at least 1% of the bacillary population 
than the later. As such, the culture-based proportion method seeks to measure the 
proportion of resistant bacilli within an Mtb population(33,41). 
Although the culture-based proportion method is universally regarded as the 
standard method for determining drug susceptibility of Mtb isolates, there are multiple 
problems with this method (42). Majority of the concerns are with the single drug 
concentration referred to as the critical concentration used to determine if an Mtb 
bacillus is resistant or susceptible. First, the critical concentrations of anti-TB drugs 
were set by general consensus without any scientific evidence (41,43,44). Secondly, the 
critical concentration of RIF and INH are set too high and ought to be lowered to 
0.0625mg/L and 0.0312mg/L, respectively (43,45). Thirdly, as shown in Table 2, the 
critical concentration of some drugs bear little relation to the concentration of the drug in 
plasma (46). Lastly, the critical concentration of drugs varies according to the growth 
medium used (Table 2) (47). The critical concentrations were initially established in 
Lowenstein-Jensen (LJ) medium. Following the development of modern solid and liquid 
media, the critical concentration in LJ media was used as a reference to establish the 
critical concentrations of other media. Although this may have seemed a straightforward 
approach, recent studies have identified some irregularities with some media such as 
with the automated BACTEC Mycobacterium Growth Indicator Tube (MGIT) 960 system 
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(44). Van Deun and colleagues (2013) showed that drug susceptibility testing using the 
BACTEC MGIT 960 system misclassified some drug-resistant Mtb isolates as drug-
susceptible. These misclassified isolates had a mutation in their drug target genes and 
were classified drug-resistant on Lowenstein Jensen media (48).  
 
Table 2. Critical concentrations for drugs used to treat drug-susceptible Mycobacterium 
tuberculosis* 
Drug Concentration in 
serum (µg /mL) 
Critical concentration (µg/mL) 
(Single drug concentration used in testing). 
  Lowenstein Jensen Middlebrook 
7H10 
Middlebrook 
7H11 
MGIT 960 
RIF 10  40 1.0 1.0 1.0 
INH 5 -10  0.2 0.2 0.2 0.1 
EMB 2 - 5  2.0 5.0 7.5 5.0 
PZA 40-50  - - - 100.0 
*Obtained with permission from (46,47). 
 
Despite the technical limitations of the culture-based proportion method, it is still 
considered the ‘gold standard’ for DST of Mtb isolates (42). However, the long 
turnaround time of this method makes it unfit for rapid DST of Mtb isolates. One to three 
months is often required before DST results become available following collection of 
specimen. Also, culturing large numbers of Mtb bacilli imposes the need for specialized 
and skilled personnel available only at centralized units. As such, the culture-based 
method is not a rapid test and cannot be used at peripheral sites. The shortcomings of 
the culture-based proportion method have fostered interest to the more rapid genotypic- 
assays for DST of Mtb (40).  
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1.4.2.1.2 Genotypic assays for diagnosing drug-resistant tuberculosis 
In 2006, the Stop TB Partnership launched its 2006-2015 initiative entitled Global 
Plan to Stop TB. One of the laudable goals of this plan was to diagnose and treat 56% 
of MDR-TB patients by 2015 (49). However, by 2008 only 7% (29,423) of the then 
annually estimated 440,000 MDR-TB cases were being diagnosed (50). The general 
consensus was that if this goal were to be attained, new drug-resistant diagnostic 
techniques had to be created. Since then, substantial progress has been made 
especially with the development of genotypic or molecular-based assays. Some of 
these molecular-based assays are now being used for the diagnosis of drug-resistant 
TB. The fast turnaround time and ease of use have led to the adoption of molecular-
based assays as the initial test for diagnosing suspected drug-resistant TB cases in 
most countries (51,52).  
Fig. 3. Adapted with permission from (111,112) . Mutations in the Rifampicin Resistance Determining 
Region (RRDR) of the rpoB gene: target of genotypic-based assays.  
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The principle of the molecular-based assays is that Mtb develops resistance to 
drugs through genetic mutations in drug-target genes (53). For example (Fig 3), RIF 
inhibits mycobacterial transcription by binding to the β-subunit of the DNA-dependent 
RNA polymerase enzyme. The β-subunit of this enzyme is encoded by the rpoB gene. 
Development of resistance to RIF is due to mutations in a well-defined, 81 base pair 
(bp) region of the rpoB gene referred to as the Rifampicin Resistance Determining 
Region (RRDR).  
 
This 81bp region, codes for amino acids 507 through 533 of the β subunit. 
Ninety-five to Ninety-six % of RIF-resistant Mtb isolates harbor mutations in this 81-bp 
region with codons 531, 526, and 516 being the most frequently reported mutation sites 
(54). As such, genotypic-based assays diagnose resistance to RIF by identifying 
mutations in the RRDR of the rpoB gene.  
Conversely, INH is a pro-drug and must be activated to its active form by the Mtb 
enzyme catalase-peroxidase (KatG) (55). The active form of INH inhibits mycolic acid 
synthesis, a cell wall component of Mtb, by binding to the enzyme keto-acyl reductase 
(inhA). As a consequence, resistance to INH could arise at one or more points in the 
KatG gene where a mutation would result in altered enzyme structure (56). This 
structural change could result to decrease conversion of INH to its active form. 
Likewise, mutations in the promoter region of the inhA gene may lead to over-
expression of the enzyme, thereby diminishing the effectiveness of INH (57). About 80% 
of INH resistant isolates have mutations in either KatG gene or inhA promoter region 
(58). As such, genotypic assays diagnose resistance to INH by detecting mutations in 
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the KatG gene and in the promoter region of inhA gene. Specifically, these assays seek 
to detect a mutation in codon 315 of the KatG gene that leads to a change in amino acid 
from Ser to Thr, and four nucleic acid mutations in the promoter region of the inhA gene 
(59,60). These four nucleic acid mutations are a mutation at position -15 from C-T, a 
mutation at position -16 from A to G and a mutation at position -8 from T to either C or A 
(57,61). Besides RIF and INH, a list of genes and mutations associated with drug-
resistance in Mtb to other drugs is available in several reviews (53,62,63).  
At present, WHO has endorsed two commercially available molecular-based 
assays for drug susceptibility testing of Mtb to RIF and INH; the line probe assay (LPA) 
(64) and the Xpert Mtb/RIF assay (40). The LPA is a 3-step assay. First DNA is 
extracted from cultured Mtb isolates or directly from clinical specimens. Secondly, the 
gene under investigation is amplified by PCR using biotinylated primers. Lastly, the 
PCR products are hybridized to specific oligonucleotide sequences immobilized on a 
strip. Once captured, the biotin-labelled hybridized products are detected by colorimetric 
reactions that create colored bands on the strip at the sites of hybridization. The LPA 
detects the presence of Mtb and the presence of mutations in the drug target genes for 
RIF and INH. If a mutation is present in one of the target regions, the amplicon will not 
hybridize to the wild-type probe on the membrane. If the mutation is one of the frequent 
mutations, the amplicon will bind with the mutation probe. Two commercial LPAs are 
currently available: the INNO-LiPA Rif. TB test (Innogenetics NV, Gent, Belgium) and 
the Genotype MTBDRplus test (Hain Lifescience Gmbh, Nehren, Germany) (65). Both 
LPAs detect Mtb and resistance to RIF, but only the Genotype MTBDRplus detects 
resistance to INH. Systematic reviews on the performance of LPAs reported good 
  
14 
accuracy for detecting resistance to RIF and INH (31,66–69). Arentz and colleagues 
(2013) reported a pooled sensitivity and specificity of 94.1% and 98.8%, respectively for 
the detection of resistance to RIF for the INNO LiPA RIF test (66). In a recent meta-
analysis, Bai and colleagues (2016) reported a pooled sensitivity of 91% for resistance 
to INH, 96% for resistance to RIF and 91% for MDR-TB. The pooled specificity were 
99% for INH; 98% for RIF and 99% for MDR-TB for the Genotype MTBDRplus assay 
(68). 
The Xpert Mtb/RIF assay (Cepheid, Sunnyvale, CA, USA) is a semi-nested real-
time nucleic acid amplification test. The test simultaneously detects Mtb and resistance 
to RIF within 2 hours. A 2014 Cochrane review concluded that the Xpert Mtb/RIF assay 
provides accurate results when used for the diagnosis of RIF resistance (70). The 
review reported a pooled sensitivity and specificity of 95% and 98% for the detection of 
RIF resistance by the Xpert MTB/RIF assay (70).  
To date, only two published studies have directly compared the performance of 
the LPA and Xpert MTB/RIF for the detection of resistance to RIF. Unfortunately, the 
studies reported different results. Rufai and colleagues (2014) reported a superiority of 
the LPA over the Xpert MTB/RIF, whereas Rahman and colleagues (2016) reported the 
opposite (71,72).  
 
1.5 Host factors that increase the risk of tuberculosis treatment failure 
Besides microbial factors, host factors also play a major role towards treatment 
success or failure in TB patients. Two host factors that may increase the risk of drug 
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failure are an impaired immune response and low plasma concentration of anti-TB 
drugs (16,17,68). 
 
1.5.1 Impaired Immune Response 
Successful treatment of bacterial infections generally requires both the antibiotic 
and the host’s immune response. The antibiotic is believed to rapidly reduce the 
growing bacterial population, while the immune response eliminates any antibiotic-
evading (resistant or persistent) bacterial cells. However, when designing antibiotic 
treatment regimens, the contribution of the immune response is not considered (74,75), 
as the immune response to bacterial infections is complex. Generally, an immune 
response involves many cell types and cytokines. In addition, the immune response is 
extremely difficult to identify, making it difficult to establish a model that could be used to 
evaluate antibiotic treatment (74,75). 
Likewise, with TB, the immune response has not generally been considered 
when designing treatment regimens, even though it contributes towards treatment 
success or failure. TB treatment outcome studies report a high likelihood of treatment 
failure in patients with impaired immune systems, such as patients co-infected with HIV 
or type 2 diabetes (73,76). These patients are unable to mount an effective immune 
response to augment the drug action. As a result of treatment failure, these patients 
may suffer adverse outcomes, such as increased risk of relapse and death (16,73,77).  
Although a good immune response during TB disease is generally considered to 
complement drug action, it can antagonize drug action. A typical “good” immune 
response to TB is characterized by the formation of granulomas that is an aggregation 
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of immune cells. In human TB, granulomas are composed of an inner core of Mtb 
infected macrophages, stimulated macrophages that have differentiated into 
multinucleated giant cells, epithelioid cells, and foamy macrophages and neutrophils. 
The inner core of cells is surrounded by a rim of lymphocytes, that consist largely of 
CD4+ T cells, CD8+ T cells, B cells and fibroblasts (2). Granulomas help contain or wall 
off the infecting Mtb thereby avoiding dissemination. However, some Mtb bacilli can 
actually survive and replicate within these granulomas. In addition, some anti-TB drugs 
are either unable to penetrate granulomas or are present in sub-therapeutic 
concentrations. Thus, the formation of granuloma induced by the immune response 
creates a protective niche for Mtb to flourish in absence of no or low concentration of a 
drug that could lead to persisting disease and subsequent treatment failures (10,78). 
 
1.5.2 Low plasma concentration of anti-tuberculosis drugs 
Another host factor responsible for treatment failure is low plasma concentration 
(below therapeutic level) of anti-TB drugs. Low plasma concentrations of a single drug 
in the TB treatment regimen are associated with treatment failures, relapse and 
acquired drug resistance (79). As shown in Fig.4, a large proportion of patients have low 
plasma concentrations of all anti-TB drugs used in the treatment regimen including RIF,  
an indispensable drug in the TB treatment regimen (80–88). RIF affects both replicating 
and non-replicating Mtb bacilli, but it is thought to have a greater effect on non-
replicating drug-persistent Mtb bacilli residing in hypoxic conditions. This drug action of 
RIF on non-replicating persistent Mtb bacilli allowed the shortening of treatment from 12 
to 6 months (89,90). Furthermore, in a recent phase 2B trial TB patients with drug-
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susceptible TB, high dose of RIF (35mg/kg) resulted in rapid clearance of Mtb bacilli 
(culture conversion) (91). Thus, the consequences of low plasma concentrations of RIF 
are serious to the patient and influences the design of new drug-treatment regimens. 
 
1.5.3 P-glycoprotein and low plasma concentration of Rifampicin 
Low plasma concentration of orally administered RIF could be as a result of 
several factors (i) poor absorption, (ii) pre-systemic metabolism or (iii) rapid systemic 
clearance. When orally administered under fasting conditions, RIF is usually well 
absorbed and reaches peak plasma concentration within 2 hours (92). Poor absorption 
of RIF could occur when taken with food or if the patient is suffering from a predisposing 
health condition, such as diarrhea, HIV (93), or diabetes (94), that could impair drug 
absorption (95). Although these conditions may affect the absorption of RIF, not all 
patients with low plasma concentrations have these prevailing conditions (96). 
Alternatively, the low plasma concentration of RIF could be due to pre-systemic 
metabolism. Pre-systemic metabolism refers to the rapid breakdown of a drug by the 
liver or gut wall enzymes before it reaches systemic circulation (97). Pre-systemic 
Fig. 4. Proportion of TB patients with low plasma concentration of anti-TB drugs  A) 
Adapted with permission from (88). B) Adapted with permission from (113) 
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metabolism mostly affects orally administered drugs. One of the ways to bypass pre-
systemic metabolism is to administer the drug intravenously. To determine if pre-
systemic metabolism will affect the plasma concentration of a drug if administered 
orally, the plasma concentration of the drug following intravenous administration is 
compared to the plasma concentration of the same drug following oral administration 
(97). Loos and co-workers (1985) compared the plasma concentration of intravenously 
administered RIF to that of orally administered RIF and reported that the plasma 
concentration of RIF administered orally was 93% of IV administered dose. This implies 
that pre-systemic metabolism has little effect on plasma concentration of orally 
administered RIF (98). However, Loos and colleagues (1985) observed a decrease in 
plasma concentration of RIF from 93% after the first single oral dose to 68% after three 
weeks of oral administration. This reduction coincided with an increase in systemic 
clearance of RIF from 5.69 to 9.03 l/h (98). As such, variation in the systemic clearance 
of RIF could likely be the cause of low plasma concentration of RIF.   
RIF is extensively metabolized in the liver and its metabolic products are 
predominantly excreted in bile and eliminated in stool (98). As such, variation in 
systemic clearance of RIF could result from differences in the rate of clearance of RIF 
into bile. As shown in Fig 5, RIF in blood flowing through the liver is cleared by 
hepatocytes. Hepatocytes use a series of membrane transporters and metabolizing 
enzymes to extract substances from blood and excrete them into bile. The uptake 
transporter, organic anion transporter polypeptide 1b1 (OATP1B1) is expressed on the 
basolateral membrane of hepatocytes and facilitates the uptake of RIF into hepatocytes 
(99–101). Once in the hepatocyte, RIF is either metabolized by β-esterases into its 
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primary metabolite 25 deacetyl rifampicin or excreted un-metabolized (102). Both un-
metabolized and metabolized RIF are primarily excreted out of the hepatocyte into the 
bile canaliculi by the efflux pump p-glycoprotein (P-gp) expressed on the canaliculi 
(apical) membrane. Due to the ability of P-gp to move its substrates into bile even 
against a 100-1,000-fold concentration gradient (103), it constitutes the primary driving 
force for the excretion of its substrates into bile. As such, the level of expression and 
activity of P-gp may have a profound effect on the plasma concentration of RIF and its 
eventual elimination pattern.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5. Diagrammatic location of membrane transporters and hepatic clearance of RIF from 
blood into bile. Pictures of liver obtained from (114) 
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1.6 Tuberculosis in Cameroon  
 Cameroon is a central African country with a high TB burden. Cameroon is 
among the top 20 countries with the highest estimated numbers of incident TB cases 
among people living with HIV (PLHIV) (104). According to WHO, in 2015, an estimated 
26,570 people in Cameroon had active TB disease of whom 32% (8,606) were PLHIV 
(105). Pulmonary TB is the most common form of TB and diagnosis is primarily via 
detection of Mtb bacilli or acid-fact bacilli (AFB) in sputum smears of patients by 
conventional light microscopy. A patient is TB-positive if AFB are detected in at least 
one of two sputum samples (106). Once a patient is diagnosed with TB, they are 
immediately placed on the standard 6-month TB regimen and monitored through the 
DOTs program. Upon completing the 6-month treatment regimen, a smear of the 
patient’s sputum is examined for the presence of AFB. If the patient is AFB- negative, 
the patient is declared cured. However, if the patient is AFB positive, he or she 
undergoes to drug susceptibility testing to determine if the patient harbors drug-resistant 
Mtb bacilli. If the AFB-positive patient is drug-susceptible, the patient is classified as 
‘retreatment’ and placed on an 8-month regimen composed of RIF, INH, PZA, EMB, and 
Streptomycin. Alternatively, if the AFB-positive patient is drug resistant, a new treatment 
regimen is administered to the patient based on the type of drug resistance (4)  
 
1.6.1 Drug-resistant tuberculosis in Cameroon 
The actual burden of drug resistance in Cameroon is not known due to the 
limited capacity to provide routine DST to all TB patients. Even in high-risk patient 
groups such previously treated TB patients for whom DST is recommended, not all 
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patients are tested. Nonetheless, epidemiological studies conducted in different regions 
of the country report 7 to 23% Mtb resistance to a single drug in the 6 months regimen 
among newly diagnosed TB patients and 16.6 to 41% among previously treated TB 
patients (107,108). Beside mono-resistance, other severe forms of resistance, such as 
MDR-TB, have been reported. Recent WHO estimates suggest that each year about 
3.2% new pulmonary TB patients in Cameroon have MDR-TB and another 14% of 
previously treated pulmonary TB patients develop MDR-TB (105).  
 
1.6.2 Diagnosing drug-resistant tuberculosis in Cameroon 
Prior to 2010, the only laboratory in Cameroon that performed DST of Mtb 
isolates was The National Tuberculosis Reference Laboratory (109). All clinical 
specimens or Mtb cultures from presumptive drug-resistant patients were sent to this 
laboratory for DST. This laboratory used culture-based proportion method on 
Lowenstein-Jensen medium for DST (109). However, in 2010, the government of 
Cameroon signed an agreement with the Expand Access to New Diagnostics for TB 
(EXPAND-TB) program. The EXPAND-TB program, a UNITAID funded program, built 
two TB DST laboratories in the cities of Bamenda and Douala and equipped all 
laboratories with the rapid liquid culture based system, BACTEC MGIT 960 system and 
the LPA assay, Genotype MTBDRplus (110). Subsequently, in 2012, the National 
Tuberculosis program in Cameroon (NTCP) received financial support from several 
international donor organizations to purchase and introduce the Xpert MTB/RIF assay in 
the three TB DST laboratories and at some TB treatment centers. At present, the Xpert 
MTB/RIF assay is used as the initial assay to test all previously treated TB patients for 
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resistance to RIF. If RIF-resistance positive, the test results must be confirmed with 
either the Genotype MTBDRplus and or BACTEC MGIT 960 system.  
1.7 Study Aims 
Successful treatment of TB requires consideration of, and medical attention to, a 
combination of microbial and host factors. Patients infected with drug-resistant Mtb 
bacilli are likely to fail treatment. Likewise, patients with low plasma drug concentrations 
are likely to experience treatment failures. Accordingly, to ensure patients have a 
successful treatment outcome, we need to diagnose drug-resistant Mtb and understand 
why some patients have lower than expected drug plasma concentrations.  
Therefore, the overall objectives of this dissertation were to determine if use of 
the genotypic assay, Genotype MTBDRplus, can be used to distinguish resistant from 
susceptible Mtb isolates in Cameroonian TB patients and to investigate if P-gp might be 
responsible for variation in plasma concentration of RIF. Specifically, we propose to:  
Aim # 1: Test the hypothesis that the Genotype MTBDRplus assay that detects four 
mutations for RIF and five mutations for INH will identify drug-resistant TB cases in 
Cameroon. We hypothesize that the Genotype MTBDRplus assay will detect all cases 
of RIF, but may not detect all INH resistant cases. 
Significance: The National Tuberculosis Control Program of Cameroon (NTCP) plans to 
use the Genotype MTBDRplus assay for the rapid diagnosis of patients with drug-
resistant TB. Our study will provide the necessary scientific evidence to guide the NTCP 
on the accuracy of this assay if adopted. 
Aim #2: Determine if failure to hybridize to wild type RIF probes and absence of 
hybridization to known mutation probes in the Genotype MTBDRplus assay indicates a 
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technical problem with the assay or presence of additional mutations. The manufacturer 
of the Genotype MTBDRplus assay recommends that a test sample should be 
interpreted as resistant if there is absence of hybridization to the wild-type probe and 
presence or absence of hybridization to a RIF-mutation probe. However, in cases that 
fail to hybridize to the RIF mutation probe, this outcome does not identify the type of 
mutation present and whether the mutation is associated with resistance to RIF. 
Sequencing of the rpoB genes of Mtb isolates with such Genotype MTBDRplus results 
will help determine if novel, RIF-resistant mutations are present. 
Significance: Our study will help determine if one of the recommendations for 
interpreting the Genotype MTBDRplus assay appropriately classifies RIF resistant 
cases.  
Aim #3: Determine the level of expression of P-gp in the liver of children, adults and the 
elderly. We hypothesize that P-gp is likely expressed from birth based on its critical 
contribution to hepatic transport functions, but that expression levels take time to reach 
adult levels and vary between individuals. 
Significance: If the expression of P-gp is determined to be the root cause of low plasma 
concentration of RIF due to developmental dynamics and/or inter-individual variability, 
then modulating the effect of P-gp on systemic drug levels with specific inhibitors can be 
conducted to identify inhibitors that prevent low plasma concentration of RIF. 
Knowing precisely the drug-susceptibility status of TB patients is important for the 
adequate treatment of TB patients. Most National Tuberculosis Control Programs, 
including that of Cameroon, plan to introduce molecular-based assays such as the 
Genotype MTBDRplus assay for drug-susceptibility testing of TB patients. This assay is 
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able to quickly identify drug-resistant TB; thereby, allowing the administration of 
adequate and timely treatment regimens. However, it is not known if this assay will 
adequately detect drug-resistant TB. Our proposed study will provide the necessary 
scientific evidence to guide National Tuberculosis Program of Cameroon on whether to 
introduce or not the Genotype MTBDRplus system as a means to rapidly diagnose drug 
resistant TB.  Also ensuring TB patients receive optimal concentration of drugs is 
necessary to ensure good treatment outcome. Our investigation of the p-gp in human 
livers will provide a plausible explanation for low plasma concentration of RIF in 
patients. Knowledge of p-gp expression will provide the opportunity to enhance the 
plasma concentration of RIF by modulating the effect of p-gp.  
 
  
25 
References 
1.  WHO | Global tuberculosis report 2016. WHO. 2016;  
2.  O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MPRR. The 
immune response in tuberculosis. [Internet]. Vol. 31, Annual review of 
immunology.  Annual Reviews ; 2013 [cited 2016 Nov 12]. 475-527 p. Available 
from: http://dx.doi.org/10.1146/annurev-immunol-032712-
095939%5Cnhttp://www.annualreviews.org/doi/pdf/10.1146/annurev-immunol-
032712-095939%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/23516984 
3.  Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol 
[Internet]. 2010 Jul 1 [cited 2016 Nov 12];185(1):15–22. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20562268 
4.  WHO | Guidelines for treatment of tuberculosis. WHO. 2015;  
5.  Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. In: 
Karumbi J, editor. Cochrane Database of Systematic Reviews [Internet]. 
Chichester, UK: John Wiley & Sons, Ltd; 2015 [cited 2016 Nov 21]. Available 
from: http://doi.wiley.com/10.1002/14651858.CD003343.pub4 
6.  TB case and treatment outcome definitions. 2014;  
7.  Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et 
al. American Thoracic Society/Centers for Disease Control and 
Prevention/Infectious Diseases Society of America. Am J Respir Crit Care Med 
[Internet]. 2003 Feb 15 [cited 2016 Dec 1];167(4):603–62. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/12588714 
8.  Millet J-P, Orcau A, de Olalla PG, Casals M, Rius C, Caylà JA. Tuberculosis 
  
26 
recurrence and its associated risk factors among successfully treated patients. J 
Epidemiol Community Health [Internet]. 2009 Oct [cited 2016 Nov 21];63(10):799–
804. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19179367 
9.  Millet J-P, Shaw E, Orcau À, Casals M, Miró JM, Caylà JA, et al. Tuberculosis 
Recurrence after Completion Treatment in a European City: Reinfection or 
Relapse? Mokrousov I, editor. PLoS One [Internet]. 2013 Jun 11 [cited 2016 Nov 
21];8(6):e64898. Available from: http://dx.plos.org/10.1371/journal.pone.0064898 
10.  Horsburgh CR, Barry CE, Lange C. Treatment of Tuberculosis. Longo DL, editor. 
N Engl J Med [Internet]. 2015 Nov 26 [cited 2016 Nov 21];373(22):2149–60. 
Available from: http://www.nejm.org/doi/10.1056/NEJMra1413919 
11.  Sacchettini JC, Rubin EJ, Freundlich JS. Drugs versus bugs: in pursuit of the 
persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol [Internet]. 
2008 Jan [cited 2016 Nov 21];6(1):41–52. Available from: 
http://www.nature.com/doifinder/10.1038/nrmicro1816 
12.  Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, et al. 
Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced 
Efflux Mechanism. Cell [Internet]. 2011 Apr [cited 2016 Nov 21];145(1):39–53. 
Available from: http://linkinghub.elsevier.com/retrieve/pii/S0092867411001747 
13.  Adams KN, Szumowski JD, Ramakrishnan L. Verapamil, and Its Metabolite 
Norverapamil, Inhibit Macrophage-induced, Bacterial Efflux Pump-mediated 
Tolerance to Multiple Anti-tubercular Drugs. J Infect Dis [Internet]. 2014 Aug 1 
[cited 2016 Nov 21];210(3):456–66. Available from: 
http://jid.oxfordjournals.org/lookup/doi/10.1093/infdis/jiu095 
  
27 
14.  Wakamoto Y, Dhar N, Chait R, Schneider K, Signorino-Gelo F, Leibler S, et al. 
Dynamic Persistence of Antibiotic-Stressed Mycobacteria. Science (80- ) 
[Internet]. 2013 Jan 4 [cited 2016 Nov 21];339(6115):91–5. Available from: 
http://www.sciencemag.org/cgi/doi/10.1126/science.1229858 
15.  Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus 
on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg 
[Internet]. 2009 Apr [cited 2016 Nov 21];80(4):634–9. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/19346391 
16.  Tweya H, Feldacker C, Phiri S, Ben-Smith A, Fenner L, Jahn A, et al. Comparison 
of Treatment Outcomes of New Smear-Positive Pulmonary Tuberculosis Patients 
by HIV and Antiretroviral Status in a TB/HIV Clinic, Malawi. Ho W, editor. PLoS 
One [Internet]. 2013 Feb 15 [cited 2016 Nov 21];8(2):e56248. Available from: 
http://dx.plos.org/10.1371/journal.pone.0056248 
17.  Grant SS, Hung DT. Persistent bacterial infections, antibiotic tolerance, and the 
oxidative stress response. Virulence [Internet]. 2013 May 15 [cited 2016 Nov 
21];4(4):273–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23563389 
18.  Gomez JE, McKinney JD, McDermott W, Ehrlich P, Waksman SA, Dye C, et al. 
M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 
[Internet]. 2004 [cited 2016 Nov 21];84(1–2):29–44. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/14670344 
19.  Brauner A, Fridman O, Gefen O, Balaban NQ. Distinguishing between resistance, 
tolerance and persistence to antibiotic treatment. Nat Rev Microbiol [Internet]. 
2016 Apr 15 [cited 2016 Nov 21];14(5):320–30. Available from: 
  
28 
http://www.nature.com/doifinder/10.1038/nrmicro.2016.34 
20.  Torrey HL, Keren I, Via LE, Lee JS, Lewis K, Dye C, et al. High Persister Mutants 
in Mycobacterium tuberculosis. Kaufmann GF, editor. PLoS One [Internet]. 2016 
May 13 [cited 2016 Nov 22];11(5):e0155127. Available from: 
http://dx.plos.org/10.1371/journal.pone.0155127 
21.  Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of 
drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis [Internet]. 1980 
Jun [cited 2016 Nov 21];121(6):939–49. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/6774638 
22.  Ahmad Z, Klinkenberg LG, Pinn ML, Fraig MM, Peloquin CA, Bishai WR, et al. 
Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-
resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis [Internet]. 
2009 Oct 1 [cited 2016 Dec 1];200(7):1136–43. Available from: 
http://jid.oxfordjournals.org/lookup/doi/10.1086/605605 
23.  Gumbo T, Louie A, Liu W, Ambrose PG, Bhavnani SM, Brown D, et al. Isoniazid’s 
bactericidal activity ceases because of the emergence of resistance, not depletion 
of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis [Internet]. 
2007 Jan 15 [cited 2016 Nov 21];195(2):194–201. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/17191164 
24.  Keren I, Minami S, Rubin E, Lewis K. Characterization and transcriptome analysis 
of Mycobacterium tuberculosis persisters. MBio [Internet]. 2011 [cited 2016 Nov 
22];2(3):e00100-11. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/21673191 
  
29 
25.  Walter ND, Dolganov GM, Garcia BJ, Worodria W, Andama A, Musisi E, et al. 
Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During 
Treatment of Human Tuberculosis. J Infect Dis [Internet]. 2015 Sep 15 [cited 2016 
Nov 22];212(6):990–8. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25762787 
26.  Honeyborne I, McHugh TD, Kuittinen I, Cichonska A, Evangelopoulos D, 
Ronacher K, et al. Profiling persistent tubercule bacilli from patient sputa during 
therapy predicts early drug efficacy. BMC Med [Internet]. 2016 Dec 7 [cited 2016 
Nov 22];14(1):68. Available from: 
http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0609-3 
27.  Singh R, Barry CE, Boshoff HIM. The three RelE homologs of Mycobacterium 
tuberculosis have individual, drug-specific effects on bacterial antibiotic tolerance. 
J Bacteriol [Internet]. 2010 Mar [cited 2016 Nov 26];192(5):1279–91. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/20061486 
28.  Aldridge BB, Fernandez-Suarez M, Heller D, Ambravaneswaran V, Irimia D, 
Toner M, et al. Asymmetry and Aging of Mycobacterial Cells Lead to Variable 
Growth and Antibiotic Susceptibility. Science (80- ). 2012;335(6064).  
29.  Wakamoto Y, Dhar N, Chait R, Schneider K, Signorino-Gelo F, Leibler S, et al. 
Dynamic Persistence of Antibiotic-Stressed Mycobacteria. Science (80- ) 
[Internet]. 2013 Jan 4 [cited 2016 Nov 21];339(6115):91–5. Available from: 
http://www.sciencemag.org/cgi/doi/10.1126/science.1229858 
30.  Cohen NR, Lobritz MA, Collins JJ. Microbial persistence and the road to drug 
resistance. Cell Host Microbe [Internet]. 2013 Jun 12 [cited 2016 Nov 
  
30 
26];13(6):632–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23768488 
31.  Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, et al. 
Persisting positron emission tomography lesion activity and Mycobacterium 
tuberculosis mRNA after tuberculosis cure. Nat Med [Internet]. 2016 Sep 5 [cited 
2016 Nov 26];22(10):1094–100. Available from: 
http://www.nature.com/doifinder/10.1038/nm.4177 
32.  Macgowan AP, BSAC Working Parties on Resistance Surveillance. Clinical 
implications of antimicrobial resistance for therapy. J Antimicrob Chemother 
[Internet]. 2008 Nov [cited 2016 Nov 28];62 Suppl 2(suppl 2):ii105-14. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/18819975 
33.  Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, et al. 
Advances in techniques of testing mycobacterial drug sensitivity, and the use of 
sensitivity tests in tuberculosis control programmes. Bull World Health Organ 
[Internet]. 1969 [cited 2016 Dec 3];41(1):21–43. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/5309084 
34.  MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB).  
35.  Sotgiu G, Tiberi S, D’Ambrosio L, Centis R, Zumla A, Migliori GB, et al. WHO 
recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet 
[Internet]. 2016 Jun [cited 2016 Nov 11];387(10037):2486–7. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S0140673616307292 
36.  Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York 
City — Turning the Tide. N Engl J Med [Internet]. 1995 Jul 27 [cited 2016 Dec 
1];333(4):229–33. Available from: 
  
31 
http://www.nejm.org/doi/abs/10.1056/NEJM199507273330406 
37.  Outbreak of Multidrug-Resistant Tuberculosis at a Hospital -- New York City, 1991 
[Internet]. [cited 2016 Dec 15]. Available from: 
https://www.cdc.gov/mmwr/preview/mmwrhtml/00020788.htm 
38.  New York City Department of Health and Mental Hygiene. Bureau of Tuberculosis 
Control Annual Summary 2015. tuberculosis in new york city, 2015 new york city 
bureau of tuberculosis control annual summary.  
39.  WHO | TB drug resistance types. WHO [Internet]. 2015 [cited 2017 Mar 29]; 
Available from: http://www.who.int/tb/areas-of-work/drug-resistant-tb/types/en/ 
40.  WHO | New rapid tests for drug-resistant TB for developing countries. WHO. 
2010;  
41.  CANETTI G, FROMAN S, GROSSET J, HAUDUROY P, LANGEROVA M, 
MAHLER HT, et al. MYCOBACTERIA: LABORATORY METHODS FOR 
TESTING DRUG SENSITIVITY AND RESISTANCE. Bull World Health Organ 
[Internet]. 1963 [cited 2016 Dec 3];29:565–78. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/14102034 
42.  Domínguez J, Boettger EC, Cirillo D, Cobelens F, Eisenach KD, Gagneux S, et al. 
Clinical implications of molecular drug resistance testing for Mycobacterium 
tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis 
[Internet]. 2016 Jan 1 [cited 2016 Dec 3];20(1):24–42. Available from: 
http://openurl.ingenta.com/content/xref?genre=article&issn=1027-
3719&volume=20&issue=1&spage=24 
43.  Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs 
  
32 
based on antimicrobial pharmacokinetic/pharmacodynamic science and 
population pharmacokinetic variability. Antimicrob Agents Chemother [Internet]. 
2010 Apr [cited 2016 Dec 3];54(4):1484–91. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20086150 
44.  Sturegård E, Ängeby KA, Werngren J, Juréen P, Kronvall G, Giske CG, et al. 
Little difference between minimum inhibitory concentrations of Mycobacterium 
tuberculosis wild-type organisms determined with BACTEC MGIT 960 and 
Middlebrook 7H10. CMI. 2014;21:148.e5-148.e7.  
45.  Gumbo T, Pasipanodya JG, Wash P, Burger A, McIlleron H. Redefining Multidrug-
Resistant Tuberculosis Based on Clinical Response to Combination Therapy. 
Antimicrob Agents Chemother [Internet]. 2014 Oct 1 [cited 2016 Dec 
3];58(10):6111–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25092691 
46.  Böttger EC. The ins and outs of Mycobacterium tuberculosis drug susceptibility 
testing. Clin Microbiol Infect [Internet]. 2011 Aug [cited 2016 Dec 3];17(8):1128–
34. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1198743X14629396 
47.  Barrera L, Cooreman E, Iragena J de D, Drobniewski F, Duda P, Havelkova M, et 
al. Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line 
Antituberculosis Drugs [Internet]. Policy Guidance on Drug-Susceptibility Testing 
(DST) of Second-Line Antituberculosis Drugs. World Health Organization; 2008 
[cited 2017 Jan 20]. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26290924 
48.  Van Deun A, Aung KJM, Bola V, Lebeke R, Hossain MA, de Rijk WB, et al. 
Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J 
  
33 
Clin Microbiol [Internet]. 2013 Aug [cited 2016 Dec 6];51(8):2633–40. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/23761144 
49.  WHO Library Cataloguing-in-Publication Data.  
50.  Multidrug and extensively drug-resistant TB (M/XDR-TB) 2010 GLOBAL REPORT 
ON SURVEILLANCE AND RESPONSE.  
51.  Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, et al. Advances 
in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a 
point-of-care test. Lancet Infect Dis. 2013;13(4):349–61.  
52.  Osman M, Simpson JA, Caldwell J, Bosman M, Nicol MP. GeneXpert MTB/RIF 
version G4 for identification of rifampin-resistant tuberculosis in a programmatic 
setting. J Clin Microbiol [Internet]. 2014 Feb [cited 2016 Dec 8];52(2):635–7. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24478501 
53.  Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB. Systematic 
review of allelic exchange experiments aimed at identifying mutations that confer 
drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 
[Internet]. 2014 Feb 1 [cited 2016 Dec 8];69(2):331–42. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/24055765 
54.  Somoskovi A, Parsons LM, Salfinger M, Jarlier W, Nikaido H, Lee R, et al. The 
molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in 
Mycobacterium tuberculosis. Respir Res [Internet]. 2001 [cited 2016 Dec 
8];2(3):164. Available from: http://respiratory-
research.biomedcentral.com/articles/10.1186/rr54 
55.  Timmins GS, Deretic V. Mechanisms of action of isoniazid. Mol Microbiol 
  
34 
[Internet]. 2006 Dec [cited 2017 Mar 29];62(5):1220–7. Available from: 
http://doi.wiley.com/10.1111/j.1365-2958.2006.05467.x 
56.  Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase—peroxidase gene and 
isoniazid resistance of Mycobacterium tuberculosis. Nature [Internet]. 1992 Aug 
13 [cited 2017 Mar 29];358(6387):591–3. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/1501713 
57.  Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden 
JD. Characterization of the catalase-peroxidase gene (katG) and inhA locus in 
isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by 
automated DNA sequencing: restricted array of mutations associated with drug 
resistance. J Infect Dis [Internet]. 1996 Jan [cited 2016 Dec 8];173(1):196–202. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/8537659 
58.  Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic Mutations Associated 
with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review. 
PLoS One. 2015 Mar;10(3).  
59.  Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the 
genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in 
Mycobacterium tuberculosis complex isolates. J Clin Microbiol [Internet]. 2005 
Aug 1 [cited 2017 Mar 24];43(8):3699–703. Available from: 
http://jcm.asm.org/cgi/doi/10.1128/JCM.43.8.3699-3703.2005 
60.  Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType 
MTBDRplus Assay for Rifampin and Isoniazid Susceptibility Testing of 
Mycobacterium tuberculosis Strains and Clinical Specimens. J Clin Microbiol. 
  
35 
2007 Aug;45(8):2635–40.  
61.  Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent 
resistance inMycobacterium tuberculosis: 1998 update. Tuber Lung Dis [Internet]. 
1998 [cited 2016 Dec 8];79(1):3–29. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/10645439 
62.  Victor TC, Helden PD van, Warren R. Prediction of Drug Resistance in M. 
tuberculosis: Molecular Mechanisms, Tools, and Applications. IUBMB Life 
(International Union Biochem Mol Biol Life) [Internet]. 2002 Apr 1 [cited 2016 Dec 
8];53(4–5):231–7. Available from: http://doi.wiley.com/10.1080/15216540212642 
63.  Lin S-YG, Desmond EP. Molecular Diagnosis of Tuberculosis and Drug 
Resistance. Clin Lab Med [Internet]. 2014 Jun [cited 2016 Dec 8];34(2):297–314. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24856529 
64.  Organization WH. WHO policy Statement: Molecular line probe assays for rapid 
screening of patients at risk of multi-drug resistant tuberculosis (MDR-TB). 
Geneva, Switzerland. 2008.  
65.  GenoType MTBDRplus | Detection resistance to rifampicin and/or isoniazid of 
MTBC complex [Internet]. [cited 2016 Dec 13]. Available from: http://www.hain-
lifescience.de/en/products/microbiology/mycobacteria/tuberculosis/genotype-
mtbdrplus.html 
66.  Arentz M, Sorensen B, Horne DJ, Walson JL. Systematic Review of the 
Performance of Rapid Rifampicin Resistance Testing for Drug-Resistant 
Tuberculosis. Dheda K, editor. PLoS One [Internet]. 2013 Oct 3 [cited 2016 Dec 
13];8(10):e76533. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24098523 
  
36 
67.  Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of 
multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J. 2008 
Nov;32(5):1165–74.  
68.  Bai Y, Wang Y, Shao C, Hao Y, Jin Y. GenoType MTBDRplus Assay for Rapid 
Detection of Multidrug Resistance in Mycobacterium tuberculosis: A Meta-
Analysis. PLoS One. 2016;11(3):e0150321.  
69.  Morgan M, Kalantri S, Flores L, Pai M, Heifets L, Cangelosi G, et al. A commercial 
line probe assay for the rapid detection of rifampicin resistance in Mycobacterium 
tuberculosis: a systematic review and meta-analysis. BMC Infect Dis [Internet]. 
2005 Dec 28 [cited 2016 Dec 13];5(1):62. Available from: 
http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-5-62 
70.  Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® 
MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. In: 
Steingart KR, editor. Cochrane Database of Systematic Reviews [Internet]. 
Chichester, UK: John Wiley & Sons, Ltd; 2014 [cited 2016 Dec 13]. p. CD009593. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24448973 
71.  Rufai SB, Kumar P, Singh A, Prajapati S, Balooni V, Singh S. Comparison of 
Xpert MTB/RIF with Line Probe Assay for Detection of Rifampin-Monoresistant 
Mycobacterium tuberculosis. J Clin Microbiol [Internet]. 2014 Jun 1 [cited 2017 
Jan 2];52(6):1846–52. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/24648554 
72.  Rahman A, Sahrin M, Afrin S, Earley K, Ahmed S, Rahman SMM, et al. 
Comparison of Xpert MTB/RIF Assay and GenoType MTBDRplus DNA Probes for 
  
37 
Detection of Mutations Associated with Rifampicin Resistance in Mycobacterium 
tuberculosis. Manganelli R, editor. 2016 Apr 7 [cited 2017 Jan 2];11(4):e0152694. 
Available from: http://dx.plos.org/10.1371/journal.pone.0152694 
73.  Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact 
of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Med 
[Internet]. 2011 Dec 1 [cited 2016 Dec 9];9(1):81. Available from: 
http://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-9-81 
74.  Handel A, Margolis E, Levin BR. Exploring the role of the immune response in 
preventing antibiotic resistance. J Theor Biol [Internet]. 2009 Feb 21 [cited 2016 
Dec 9];256(4):655–62. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/19056402 
75.  Ankomah P, Levin BR. Exploring the collaboration between antibiotics and the 
immune response in the treatment of acute, self-limiting infections. Proc Natl Acad 
Sci U S A [Internet]. 2014 Jun 10 [cited 2016 Dec 9];111(23):8331–8. Available 
from: http://www.pnas.org/cgi/doi/10.1073/pnas.1400352111 
76.  Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two 
epidemics. Lancet Infect Dis [Internet]. 2009 Dec [cited 2016 Dec 14];9(12):737–
46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19926034 
77.  Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, et al. Treatment of 
active tuberculosis in HIV-coinfected patients: a systematic review and meta-
analysis. Clin Infect Dis [Internet]. 2010 May 1 [cited 2016 Dec 10];50(9):1288–99. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/20353364 
78.  Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to 
  
38 
mycobacterial cells. Nat Rev Microbiol [Internet]. 2014 Mar [cited 2016 Dec 
10];12(3):159–67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24487820 
79.  Pasipanodya JG, Srivastava S, Gumbo T. Meta-Analysis of Clinical Studies 
Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug 
Resistance and Failure of Antituberculosis Therapy. Clin Infect Dis [Internet]. 
2012 Jul 15 [cited 2016 Dec 12];55(2):169–77. Available from: 
http://cid.oxfordjournals.org/lookup/doi/10.1093/cid/cis353 
80.  Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree 
MJ, et al. Pharmacokinetics of First-Line Tuberculosis Drugs in Tanzanian 
Patients. Antimicrob Agents Chemother [Internet]. 2013 Jul 1 [cited 2016 Dec 
12];57(7):3208–13. Available from: 
http://aac.asm.org/cgi/doi/10.1128/AAC.02599-12 
81.  Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow 
response to tuberculosis treatment in a state control program, Virginia, USA. 
Emerg Infect Dis [Internet]. 2010 Oct [cited 2016 Dec 12];16(10):1546–53. 
Available from: http://wwwnc.cdc.gov/eid/article/16/10/10-0374_article.htm 
82.  Um S-W, Lee SW, Kwon SY, Yoon HI, Park KU, Song J, et al. Low serum 
concentrations of anti-tuberculosis drugs and determinants of their serum levels. 
Int J Tuberc Lung Dis [Internet]. 2007 Sep [cited 2016 Dec 12];11(9):972–8. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/17705974 
83.  Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, et 
al. Serum concentrations of antimycobacterial drugs in patients with pulmonary 
tuberculosis in Botswana. Clin Infect Dis [Internet]. 2005 Aug 15 [cited 2016 Dec 
  
39 
12];41(4):461–9. Available from: 
http://cid.oxfordjournals.org/lookup/doi/10.1086/431984 
84.  Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, et al. 
Isoniazid, Rifampin, and Pyrazinamide Plasma Concentrations in Relation to 
Treatment Response in Indonesian Pulmonary Tuberculosis Patients. Antimicrob 
Agents Chemother [Internet]. 2013 Aug 1 [cited 2016 Dec 12];57(8):3614–9. 
Available from: http://aac.asm.org/cgi/doi/10.1128/AAC.02468-12 
85.  Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, et al. 
Association between acquired rifamycin resistance and the pharmacokinetics of 
rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 
[Internet]. 2005 May 15 [cited 2016 Dec 12];40(10):1481–91. Available from: 
http://cid.oxfordjournals.org/lookup/doi/10.1086/429321 
86.  Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low 
serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. 
Chest [Internet]. 1998 May [cited 2016 Dec 12];113(5):1178–83. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/9596291 
87.  Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-Resistant 
Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic 
Variability. J Infect Dis [Internet]. 2011 Dec 15 [cited 2016 Dec 12];204(12):1951–
9. Available from: http://jid.oxfordjournals.org/lookup/doi/10.1093/infdis/jir658 
88.  Park JS, Lee J-Y, Lee YJ, Kim SJ, Cho Y-J, Yoon H Il, et al. Serum Levels of 
Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome. 
Antimicrob Agents Chemother [Internet]. 2015 Oct 12 [cited 2016 Dec 
  
40 
12];60(1):92–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26459901 
89.  Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: 
current standards and recent advances. Insights from the Society of Infectious 
Diseases Pharmacists. Pharmacotherapy [Internet]. 2009 Dec [cited 2016 Dec 
12];29(12):1468–81. Available from: http://doi.wiley.com/10.1592/phco.29.12.1468 
90.  WHO | <em>Treatment of Tuberculosis: guidelines for national 
programmes</em>. WHO. 2014;  
91.  Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, et al. A 
Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of 
Tuberculosis. Am J Respir Crit Care Med [Internet]. 2015 May 1 [cited 2016 Dec 
15];191(9):1058–65. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25654354 
92.  Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet [Internet]. 
[cited 2017 Mar 30];3(2):108–27. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/346286 
93.  Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, 
Padmapriyadarsini C, Swaminathan S, et al. Decreased Bioavailability of 
Rifampin and Other Antituberculosis Drugs in Patients with Advanced Human 
Immunodeficiency Virus Disease. Antimicrob Agents Chemother [Internet]. 2004 
Nov 1 [cited 2017 Mar 30];48(11):4473–5. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/15504887 
94.  Medellín-Garibay SE, Cortez-Espinosa N, Milán-Segovia RC, Magaña-Aquino M, 
Vargas-Morales JM, González-Amaro R, et al. Clinical Pharmacokinetics of 
  
41 
Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association 
with Biochemical and Immunological Parameters. Antimicrob Agents Chemother 
[Internet]. 2015 Dec [cited 2017 Mar 30];59(12):7707–14. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26438503 
95.  Bento J, Duarte R, Brito MC, Leite S, Lobato MR, Caldeira M do C, et al. 
Malabsorption of antimycobacterial drugs as a cause of treatment failure in 
tuberculosis. BMJ Case Rep [Internet]. 2010 Sep 29 [cited 2017 Mar 30];2010. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/22778380 
96.  Ruslami R, Nijland HMJ, Adhiarta IGN, Kariadi SHKS, Alisjahbana B, Aarnoutse 
RE, et al. Pharmacokinetics of Antituberculosis Drugs in Pulmonary Tuberculosis 
Patients with Type 2 Diabetes. Antimicrob Agents Chemother [Internet]. 2010 Mar 
1 [cited 2017 Mar 30];54(3):1068–74. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20038625 
97.  George CF, Shand DG, Renwick AG. Presystemic drug elimination [Internet]. 
[cited 2017 Mar 30]. 213 p. Available from: 
http://www.sciencedirect.com/science/book/9780407023222 
98.  Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. 
Pharmacokinetics of oral and intravenous rifampicin during chronic administration. 
Klin Wochenschr [Internet]. 1985 Dec 2 [cited 2016 Dec 12];63(23):1205–11. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/4087830 
99.  Chigutsa E, Visser ME, Swart EC, Denti P, Pushpakom S, Egan D, et al. The 
SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is 
associated with reduced rifampin concentrations: dosing implications. Antimicrob 
  
42 
Agents Chemother [Internet]. 2011 Sep 1 [cited 2016 Dec 12];55(9):4122–7. 
Available from: http://aac.asm.org/cgi/doi/10.1128/AAC.01833-10 
100.  Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, et al. 
Membrane transporters in drug development. Nat Rev Drug Discov [Internet]. 
2010 Mar [cited 2016 Dec 12];9(3):215–36. Available from: 
http://www.nature.com/doifinder/10.1038/nrd3028 
101.  Weiner M, Peloquin C, Burman W, Luo C-C, Engle M, Prihoda TJ, et al. Effects of 
Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin 
Concentrations. Antimicrob Agents Chemother [Internet]. 2010 Oct 1 [cited 2016 
Dec 12];54(10):4192–200. Available from: 
http://aac.asm.org/cgi/doi/10.1128/AAC.00353-10 
102.  Jamis-Dow CA, Katki AG, Collins JM, Klecker RW. Rifampin and rifabutin and 
their metabolism by human liver esterases. Xenobiotica [Internet]. 1997 Oct 22 
[cited 2016 Dec 12];27(10):1015–24. Available from: 
http://www.tandfonline.com/doi/full/10.1080/004982597239994 
103.  Faber KN, Müller M, Jansen PLM. Drug transport proteins in the liver. Adv Drug 
Deliv Rev [Internet]. 2003 Jan 21 [cited 2016 Dec 12];55(1):107–24. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/12535576 
104.  Use of high burden country lists for TB by WHO in the post-2015 era meeting of 
WHO’s Strategic and Technical Advisory Group for TB (STAG-TB). 2015;  
105.  WHO. Tuberculosis Country Profile. Cameroon. 2015 [Internet]. [cited 2017 Jan 
2]. Available from: 
https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports
  
43 
%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=CM&LAN=EN&outtype=
html 
106.  Enarson D, Rieder H, Arnadottir T, Trébucq A. Technical guide: sputum 
examination for tuberculosis by direct microscopy in low income countries. 2000 
Jan;  
107.  Meriki HD, Tufon KA, Atanga PN, Ane-Anyangwe IN, Anong DN, Cho-Ngwa F, et 
al. Drug Resistance Profiles of Mycobacterium tuberculosis Complex and Factors 
Associated with Drug Resistance in the Northwest and Southwest Regions of 
Cameroon. Wilkinson RJ, editor. PLoS One [Internet]. 2013 Oct 16 [cited 2017 
Jan 3];8(10):e77410. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/24146991 
108.  Assam-Assam J-P, Penlap VB, Cho-Ngwa F, Tedom J-C, Ane-Anyangwe I, Titanji 
VP. Mycobacterium tuberculosis complex drug resistance pattern and 
identification of species causing tuberculosis in the West and Centre regions of 
Cameroon. BMC Infect Dis [Internet]. 2011 Dec 15 [cited 2017 Jan 3];11(1):94. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21496268 
109.  Noeske J, Voelz N, Fon E, Abena Foe J-L. Early results of systematic drug 
susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon. 
BMC Res Notes [Internet]. 2012 Mar 21 [cited 2017 Mar 30];5:160. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/22436423 
110.  EXPANDx TB (MDR-TB Diagnostics) [Internet]. [cited 2017 Jan 3]. Available from: 
http://www.unitaid.eu/en/expandx-tb-mdr-tb-diagnostics 
111.  Pierre-Audigier C, Gicquel B. The contribution of molecular biology in diagnosing 
  
44 
tuberculosis and detecting antibiotic resistance.  
112.  Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, et al. Whole-
genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains 
identifies compensatory mutations in RNA polymerase genes. Nat Genet 
[Internet]. 2011 Dec 18 [cited 2016 Dec 15];44(1):106–10. Available from: 
http://www.nature.com/doifinder/10.1038/ng.1038 
113.  Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic Drug Monitoring for Slow 
Response to Tuberculosis Treatment in a State Control Program, Virginia, USA. 
Emerg Infect Dis [Internet]. 2010 Oct [cited 2016 Dec 12];16(10):1546–53. 
Available from: http://wwwnc.cdc.gov/eid/article/16/10/10-0374_article.htm 
114.  Chapter 22: The Digestive System [Internet]. [cited 2017 Jan 20]. Available from: 
https://cms.webstudy.com/WebstudyFileSystem/testovaci/GetFile/293875/Ch 
22/Ch22b/Ch22b_print.html 
 
 
 
 
 
 
 
 
  
45 
CHAPTER 2 
 
(For submissions to BMC Infectious Diseases) 
(The following Chapter has been submitted, reviewed, and subsequently revised. 
Waiting for final decision by the journal) 
 
Diagnostic Accuracy and Usefulness of the Genotype MTBDRplus Assay in Diagnosing 
Multidrug-resistant Tuberculosis in Cameroon? A Cross-Sectional Study 
 
1) Ngu Njei Abanda. Department of Tropical Medicine, Medical Microbiology, and 
Pharmacology, University of Hawaii, Honolulu, Hawaii 96813, USA 
abandann@hawaii.edu 
2) Josiane Yvonne Djieugoué. Mycobacteriology service, Centre Pasteur of Cameroon, 
PO Box: 1274, Yaounde Cameroon. dyjosiane@yahoo.fr  
3) Eunjung Lim. Office of Biostatistics and Quantitative Health Sciences, University of 
Hawaii, Honolulu, Hawaii 96813, USA. lime@hawaii.edu  
4) Eric Walter Pefura-Yone. Pneumology service, Yaounde Jamot Hospital, P.O Box: 
4021, Yaounde, Cameroon. pefura2002@yahoo.fr. 
5) Wilfred Fon Mbacham. The Biotechnology Centre, University of Yaoundé 1, BP 8094, 
Yaoundé, Cameroon. wfmbacham@yahoo.com 
6) Guy Vernet. Virology Service, Centre Pasteur of Cameroon, P.O. Box 1274, 
Yaoundé, Cameroon. Guy.vernet@pasteur.fr  
  
46 
7) Veronique Mbeng Penlap Laboratory for Tuberculosis Research (LTR), 
Biotechnology Centre (BTC)-Nkolbison, University of Yaoundé I, Yaoundé, Cameroon. 
v.penlap@yahoo.fr. 
8) Sara Irene Eyangoh. Mycobacteriology service, Centre Pasteur of Cameroon, PO 
Box: 1274, Yaounde Cameroon.  eyangoh@pasteur-yaounde.org  
9) Diane Wallace Taylor Department of Tropical Medicine, Medical Microbiology, and 
Pharmacology, University of Hawaii, Honolulu, Hawaii 96813, USA. 
dwtaylor@hawaii.edu  
10) Rose Gana Fomban Leke. Laboratory of Immunology and Parasitology, the 
Biotechnology Centre, University of Yaoundé 1, Yaoundé, Cameroon. 
roseleke@yahoo.com. 
 
Corresponding authors: Ngu Njei Abanda. Department of Tropical Medicine, Medical 
Microbiology, and Pharmacology, University of Hawaii, Honolulu, Hawaii 96813, USA. 
abandann@hawaii.edu  
  
47 
2.1 ABSTRACT 
Background 
Drug-resistant tuberculosis, especially multidrug-resistant tuberculosis (MDR-TB), is a 
major public health problem. Effective management of MDR-TB relies on accurate and 
rapid diagnosis. In this study, we assessed the diagnostic accuracy of the Genotype 
MTBDRplus assay in diagnosing MDR-TB in Cameroon, and then discuss on its utility 
within the diagnostic algorithm for MDR-TB.  
Methods  
In this cross-sectional study, 225 isolates of Mycobacterium tuberculosis cultured from 
sputum samples collected from new and previously treated pulmonary tuberculosis 
patients in Cameroon were used to determine the accuracy of the Genotype 
MTBDRplus assay. We compared the results of the Genotype MTBDRplus assay with 
those from the automated liquid culture BACTEC MGIT 960 SIRE system for sensitivity, 
specificity, and degree of agreement. The pattern of mutations associated with 
resistance to RIF and INH were also analyzed 
Results 
The Genotype MTBDRplus assay correctly identified Rifampicin (RIF) resistance in 
48/49 isolates (sensitivity, 98% [CI, 89%-100%]), Isoniazid (INH) resistance in 55/60 
isolates (sensitivity 92% [CI, 82%-96%]), and MDR-TB in 46/49 (sensitivity, 94% [CI, 
83%-98%]). The specificity for the detection of RIF-resistant and MDR-TB cases was 
100% (CI, 98%-100%), while that of INH resistance was 99% (CI, 97%-100%). The 
agreement between the two tests for the detection of MDR-TB was very good (Kappa = 
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0.96 [CI, 0.92-1.00]). Among the 3 missed MDR-TB cases, the Genotype MTBDRplus 
assay classified two samples as RIF-monoresistant and one as INH monoresistant. 
The most frequent mutations detected by the Genotype MTBDRplus assay was the 
rpoB S531L MUT3 41/49 (84%) in RIF-resistant isolates, and the KatG S315T1 (MUT1) 
35/55 (64%) and inhA C15T (MUT1) 20/55 (36%) mutations in INH-resistant isolates. 
Conclusion 
The Genotype MTBDRplus assay had good accuracy and could be used for the 
diagnosis of MDR-TB in Cameroon. For routine MDR-TB diagnosis, this assay could be 
used for Mycobacterium tuberculosis cultures containing contaminants, to complement 
culture-based drug susceptibility testing or to determine drug resistant mutations.  
 
Keywords: Multidrug-resistant tuberculosis (MDR-TB), Genotype MTBDRplus assay, 
pulmonary tuberculosis, Cameroon. InhA promoter mutation, KatG codon 315 mutation, 
rpoB mutations.  
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2.2 BACKGROUND 
The emergence of drug-resistant tuberculosis, especially multidrug-resistant 
tuberculosis (MDR-TB), threatens TB control efforts in most countries including 
Cameroon. MDR-TB is caused by strains of Mycobacterium tuberculosis (Mtb) with in-
vitro resistance to two of the most potent anti-tuberculosis drugs, Rifampicin (RIF) and 
Isoniazid (INH) (1,2). Recent World Health Organization (WHO) estimates suggest that 
each year about 460/20882 (2.2%) new pulmonary TB (PTB) patients in Cameroon 
develop MDR-TB, and another 170/1575 (11%) previously treated PTB patients develop 
MDR-TB. Unfortunately, only a small fraction (~40%) of these patients have access to 
drug susceptibility testing (DST) for MDR-TB (3). In response to the need to expand 
access to diagnostics for patients at risk of MDR-TB, the government of Cameroon 
signed an agreement with the EXPANDx-TB program (Expand Access to New 
Diagnostics for TB) project in 2010. The EXPANDx-TB program is a UNITAID funded 
program with the overall objective to increase access to diagnostics for patients at risk 
of MDR-TB in 27 low-income and high TB burden countries, including Cameroon. In 
Cameroon, this program plans to strengthen existing MDR-TB diagnostic laboratories 
and establish new laboratories with the capacity to culture and conduct culture-based 
DST of Mtb. Also, the program introduced the Genotype MTBDRplus assay for the rapid 
diagnosis of MDR-TB (4). 
The Genotype MTBDRplus assay (Hain Lifescience GmbH, Nehren, Germany) is a 
molecular-based test that can rapidly diagnose MDR-TB. This assay detects MDR-TB 
by identifying mutations in the rpoB gene associated with resistance to RIF and in the 
KatG gene and promoter region of the inhA gene associated with INH resistance (5,6). 
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Two independent systematic reviews concluded that the Genotype MTBDRplus assay 
was highly accurate in diagnosing MDR-TB when compared to the culture-based 
proportion method (7,8). These two reviews reported pooled sensitivities of 88.7% (7) 
and 91% (8) and specificities of 99.2% (7) and 99% (8), respectively, for detection of 
MDR-TB. Although there is evidence of the accuracy of the Genotype MTBDRplus 
assay, the prevalence of MDR-TB varies widely worldwide. This variation in prevalence 
of MDR-TB might have a significant impact on the predictive value of the Genotype 
MTBDRplus assay (9). Thus, it is important to evaluate the assay before its use in 
routine diagnosis. 
In this study, we sought to determine the accuracy of the Genotype MTBDRplus assay 
to diagnose MDR-TB cases in Cameroon. Furthermore, the government of Cameroon 
has recently adopted, an alternative molecular-based test the GeneXpert MTB/RIF 
assay (Cepheid, Sunnyvale, CA, USA) for the initial screening of TB patients at risk of 
MDR-TB (10–12). The GeneXpert MTB/RIF assay simultaneously detects TB and 
resistance to RIF directly from clinical specimen within 2hours. At present, the 
government has introduced the GeneXpert MTB/RIF assay in 3 of the 10 regions of the 
country but plans to roll-out the assay to all parts of the Country (12). As such, we 
discuss on the additional use and role of the Genotype MTBDRplus assay in the 
diagnosis of MDR-TB amidst the availability of the GeneXpert MTB/RIF. 
2.3 METHODS 
Study design and setting 
Participants were enrolled at six health facilities in three towns in Cameroon, between 
April 2015 and February 2016. The health facilities were the Jamot Hospital in Yaounde 
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(3.8480 N, 11.5020 E), the Bamenda Regional Hospital in Bamenda (5.9630 N, 
10.1590E), and 4 facilities in Douala (4.0510 N, 9.7680 E) including Laquintinie Hospital, 
the St Albert the Great Hospital, the dispensary Catholic Barcelone and the New Bell 
District Hospital. These health facilities are the major TB diagnosis and treatment 
centers in their respective locations. 
Study participants 
Participants aged ≥ 15 years old visiting any of the six health facilities and diagnosed by 
the laboratory of the health facility to be sputum smear positive for acid-fast bacilli (AFB) 
or diagnosed by the consulting clinician at the health facility to have clinical symptoms 
and signs suggestive of PTB were recruited into the study. This recruitment approach, 
allowed us to enroll patients from whom sputum samples will likely yield positive Mtb 
culture.  
Although there are many naïve PTB patients (n =20,882), very few are MDR-TB (2.2%; 
n=460/20882). To include a high proportion of patients likely to have MDR-TB, , the 
initial focus was to enrol previously treated PTB patients in whom the proportion of 
MDR-TB is higher (11%; n= 170/1575) and then expand enrollment to include  naïve 
PTB patients. Written informed consent was obtained from all study participants, and a 
structured questionnaire was used to collect demographic and medical information, 
including prior PTB history, age, gender, and HIV status. An expectorated sputum 
specimen was collected from each participant and transported to the study laboratory 
for mycobacterial culture, DST and MTBDRplus assay.  
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Specimen processing and microbiology testing 
Mycobacterial culture and drug susceptibility testing were performed at the 
Mycobacteriology unit of Centre Pasteur du Cameroun in Yaounde. Within 48 hours of 
receipt of sputum samples in the laboratory, smears were made, stained using the 
auramine staining technique and examined by fluorescence microscopy. The smears 
were read and graded according to WHO guidelines and that of the International Union 
against Tuberculosis and Lung Diseases (IUALTD) (13,14). The sputum samples were 
then processed for culturing by decontaminating in Sodium hydroxide-Sodium citrate-N-
acetyl L-cysteine (NaOH-NaC-NALC) solution and cultured in MGIT tubes using the 
BACTEC MGIT 960 system (Becton Dickinson, Franklin Lakes, NJ). MGIT tubes that 
gave a positive fluorescent signal with the BACTEC MGIT 960 equipment were checked 
for acid-fast-bacilli using Ziehl-Neelsen staining and confirmed for Mtb complex (MTBC) 
using the TB Ag MPT64 test (SD Bioline, Standard Diagnostics, Suwon, Korea). 
Cultures growing MTBC were assessed for contamination with other bacteria or fungi by 
growth on blood agar medium for 24 hours at 370C. If no contaminants (i.e., Bacteria or 
fungi) were detected on the blood agar, drug susceptibility testing (DST) was performed 
using the MGIT 960 Streptomycin-Isoniazid-Rifampicin-Ethambutol (SIRE) kit (Becton 
Dickinson Diagnostic Systems). If contaminants were detected on the blood agar, the 
MTBC cultures were decontaminated and the culturing process repeated. The critical 
concentrations of Streptomycin, Rifampicin ,Isoniazid and Ethambutol used in the MGIT 
960 SIRE kit were respectively 1.0µg/ml, 1.0µg/ml, 0.1µg/ml and 5.0µg/ml. 
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Immediately the DST result of a patient’s sample was available, an aliquot of the culture 
was made and stored at +40C. Once the total number of cultures with DST results 
reached 226, the stored aliquots were screened using the Genotype MTBDRplus assay. 
Genotype MTBDRplus assay  
Samples were screened using the Genotype MTBDRplus assay according to 
manufacturer’s instructions (5) and interpreted without knowledge of susceptibility 
results determined by the MGIT SIRE 960 system. Testing consisted of three steps: 
DNA extraction using the Genolyse kit (Hain Lifescience, Nehren, Germany), multiplex 
PCR amplification using biotinylated primers and reverse hybridization. The three steps 
were carried out in three separated rooms.  
Each Genotype MTBDRplus strip had 27 reaction zones or probes that hybridize DNA 
(amplicons). Six of the probes were positive controls, while 21 probes were used to 
detect resistance to RIF and INH. For the detection of RIF resistance, the strip 
contained 8 probes that hybridize DNA from codons 506 to 533 of the rpoB gene and 4 
mutation probes (rpoBMUT1 (D516V), rpoBMUT2A (H526Y), rpoBMUT2B (H526D) and 
rpoBMUT3 (S531L)). Similarly, for INH resistance, the strip contains probes that 
hybridized DNA at codon 315 of the KatG gene and positions -1 to -22 on the inhA 
promoter region. The mutation probes associated with INH resistance were katGMUT1 
(S315T1), katGMUT2 (S315T2), inhAMUT1 (C15T), inhAMUT2 (A16G), inhAMUT3A 
(T8C), and inhAMUT3B (T8A). When the DNA amplicons hybridized to the probes on 
the Genotype MTBDRplus strip following hybridization, a dark band was produced that 
was easily interpreted as positive. 
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The Genotype MTBDRplus strips were interpreted in a two-stage process. First, the 
presence of the 6 control bands was confirmed, demonstrating the assay worked and 
that MTBC was present. Secondly, susceptibilities to RIF and INH were assessed. A 
sample was considered to be resistant to the drug if at least one of the wild-type bands 
was absent or a band indicating a common mutation in the drug resistance-related gene 
was present. Likewise, a sample was considered sensitive to the drug if all the wild-type 
bands of the gene were present and no common mutation was detected.  
Statistical methods 
Participants were classified as new, previously treated PTB patients or patients with 
unknown PTB history. Participant characteristics were compared between new and 
previously treated TB patients using two-tailed Fisher’s exact test or Chi-square test for 
categorical variables and non-parametric Mann Whitney test for continuous numerical 
variables. No adjustment for multiple comparisons was made because only a few 
planned comparisons were made and the data evaluated are actual observations (15). 
To determine the accuracy of the Genotype MTBDRplus assay to diagnose MDR-TB, 
Genotype MTBDRplus results were compared to the gold standard MGIT 960 SIRE 
system. We calculated the sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) with 95% confidence intervals (CI) of the Genotype 
MTBDRplus assay for the detection of MDR-TB and resistance to RIF and INH. 
Sensitivity was defined as the proportion of isolates correctly determined as resistant by 
the Genotype MTBDRplus assay compared with MGIT 960 SIRE system. Specificity 
was defined as the proportion of isolates correctly determined as susceptible by the 
Genotype MTBDRplus  assay compared with MGIT 960 SIRE system. PPV was defined 
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as the proportion of resistant isolates determined by the MGIT 960 SIRE system among 
isolates determined as resistant by Genotype MTBDRplus assay. NPV was defined as 
the proportion of susceptible isolates determined by the MGIT 960 SIRE system among 
isolates determined as susceptible by Genotype MTBDRplus assay. The degree of 
agreement between MGIT 960 SIRE system and the Genotype MTBDRplus assay was 
also assessed using Cohen’s kappa (ĸ) coefficient. ĸ values of >0.75 defined as 
showing very good agreement, ĸ values of <0.4 defined as showing poor agreement 
and ĸ values of 0.4-0.75 defined as showing fair to good agreement (16).  
All analyses and comparisons were done with GraphPad prism software, version 6 
(GraphPad Software, California, USA) and all results having a p<0.05 were considered 
statistically significant.  
 
2.4 RESULTS 
Demographic characteristic of the study population 
Figure 1 shows a schematic diagram of sample processing. Among the 288 participants 
recruited from 6 health facilities, 270 participants were eligible to participate in the study. 
Each eligible participant provided a sputum sample that resulted in smear microscopy 
and MGIT culture data. Of 270 MGIT cultures, 239 samples were positive for MTBC, 21 
(7.8%) were negative for growth, and 10 (3.7%) cultures had growth, but the bacteria 
were not of the MTBC. Of the 239 MGIT-MTBC positive cultures, DST was successfully 
performed on 226 (95%); Ziehl-Neelsen staining of the 13 isolates without DST results 
showed that either non-tuberculous mycobacteria or other contaminants like bacteria or 
fungi had been cultured. Among the 226 isolates with DST results, 152 (67%) were 
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susceptible to both RIF and INH, 49 (22%) were resistant to both RIF and INH, 6 (3%) 
were INH monoresistant, 5 (2%) were poly-drug-resistant (i.e., to INH plus Streptomycin 
(n=4) or INH plus Ethambutol (n=1)), and 14(6%) were Streptomycin monoresistant.  
Table 1 shows characteristics of the 270 eligible participants. The 169 previously 
treated TB patients were more likely to be recruited from Yaounde (p <0.0001), more 
likely to be HIV-negative (p = 0.0008), more likely to be sputum smear positive (p= 
0.0012), and more likely to be drug resistant (p <0.0001) than the 79 new TB patients. 
Genotype MTBDRplus test results 
The Genotype MTBDRplus assay was performed on 225 cultures with MGIT DST 
results, as one isolate was not recovered following culture of the stored sediment 
sample. Valid Genotype MTBDRplus results were obtained for all 225 cultured isolates 
on the first attempt. Table 2 provides results comparing the Genotype MTBDRplus and 
MGIT DST assays for the detection RIF-resistant, INH-resistant, and MDR-TB cases.  
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Table 2: Performance of the Genotype MTBDRplus assay in detecting resistance in 
clinical isolates of Mycobacterium tuberculosis 
Gold standard: BACTEC MGIT DST 960 System(# of Mtb isolates) 
  RIF INH MDR-TB 
Test assay 
R 
(n=49) 
S 
(n=176) 
*R 
(n=60) 
S 
(n=165) 
R 
(n=49) 
S 
(n=176) 
 Genotype 
MTBDRplus  
R 48 0 55 1 46 0 
S 1 176 5 164 3 176 
Sensitivity (95% CI) 
  
98 (89-100) 
  
92 (82-96) 
  
94 (83-98) 
Specificity (95% CI) 100 (98-100) 99 (97-100) 100 (98-100) 
PPV (95% CI) 100 (93-100) 98 (91-100) 100 (92-100) 
NPV (95% CI) 99 (97-100) 97 (93-99)  98 (95-100) 
Cohen's kappa (95% 
CI) 0.99 (0.96-1.00) 0.93 (0.88-0.99) 0.96 (0.92- 1.00) 
Abbreviations: R: Resistant; S: Susceptible; CI: Confidence interval; RIF: 
Rifampicin; INH: Isoniazid; MDR-TB: Multidrug resistant Tuberculosis; PPV: 
Positive Predictive Value; NPV: Negative Predictive Value 
* INH Resistant (n=60) refers to all INH resistant isolates that is; INH and RIF drug-
resistant (n=49), INH mono drug-resistant (n=6) and INH poly drug-resistant (n=5) 
 
Overall, the Genotype MTBDRplus assay correctly identified RIF resistance in 48/49 
(sensitivity, 98% [CI, 89%-100%]), INH resistance in 55/60 (sensitivity 92% [CI, 82%-
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96%]), and MDR-TB 46/49 (sensitivity, 94% [CI, 83%-98%]). The specificity for the 
detection of RIF resistant and MDR-TB cases was 100% (CI, 98%-100%), while that of 
INH resistant was 99% (CI, 97% -100%). The PPV and NPV of the Genotype 
MTBDRplus assay were high for RIF resistance, INH resistance and MDR-TB, ranging 
from 97%-100%. The agreement between both tests for the detection of MDR-TB was 
very good (Kappa = 0.96 [CI: 0.92-1.00]).  
All discordant results between the MGIT DST system and the Genotype MTBDRplus 
assay are shown in Table 3. The discordant isolates presented with different Genotype 
MTBDRplus resistant patterns.  
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Table 3: Discordant results between MGIT DST and Genotype MTBDRplus 
Patient 
code 
Patient 
Treatment 
history 
MGIT DST 
Genotype MTBDRplus 
assay Results 
RIF INH STM EMB rpoB KatG inhA  
HJ128 
Previously 
treated S S S S 
WT WT 
∆WT1, 
MUT1 
INH  
monoresistant 
HJ063 
Previously 
treated S R S R 
WT WT WT 
Susceptible 
HL024 
Previously 
treated S R S S 
WT WT WT 
Susceptible 
HJ088 
Previously 
treated S R S S 
WT WT WT 
Susceptible 
HJ107 
Previously 
treated R R S R 
∆WT8, 
MUT3 
WT WT 
RIF  
monoresistant 
HJ123 
Previously 
treated R R S S 
∆WT8, 
MUT3 
WT WT 
RIF  
monoresistant 
HJ064 
Previously 
treated R R R R 
WT 
∆WT1, 
MUT1 
WT 
INH  
monoresistant 
Abbreviations: S: Susceptible; R: Resistant; WT: Wild Type probe; MUT: Mutation;  
∆ Absence of hybridization signal with wild-type probe. 
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Genotype MTBDRplus mutation patterns  
The pattern of mutations associated with INH monoresistant, INH poly-resistant and 
MDR-TB isolates are shown in Table 4. Overall, the most frequent mutation detected in 
RIF-resistant isolates was the rpoB S531L MUT3 41/49 (84%). In INH-resistant isolates 
the most frequent mutations were KatG S315T1 (MUT1) 35/55 (64%) followed by inhA 
C15T (MUT1) 20/55 (36%). Majority of the KatG S315T1 mutation was detected among 
INH polydrug resistant and MDR-TB isolates. Concurrent KatG S315T1 and inhA 
promoter mutations (T8C (MUT3A)) were detected in only one isolate- an MDR-TB 
isolate.  
 
Table 4: Pattern of gene mutations detected by the Genotype MTBDRplus assay in 60 
drug-resistant Mycobacterium tuberculosis isolates 
Gene Band 
Gene 
region or 
mutations 
*INH 
monoresistant 
N=6 
*INH poly-
resistant N=5 
*MDR-TB 
(N=49) 
rpoB 
WT1 506-509 6 5 49 
WT2 510-513 6 5 48 
WT3 513-517 6 5 46 
WT4 516-519 6 5 47 
WT5 518-522 6 5 49 
WT6 521-525 6 5 49 
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WT7 526-529 6 5 46 
WT8 530-533 6 5 7 
MUT1 D516V 0 0 0 
MUT2A H526Y 0 0 0 
MUT2B H526D 0 0 3 
MUT3 S531L 0 0 41 
KatG 
     WT 315 5 1 19 
MUT1 S315T1 1 4 30 
MUT2 S315T2 0 0 
inhA 
     WT1 -15/-16 3 5 32 
WT2 -8 6 5 49 
MUT1 C15T 3 0 17 
MUT2 A16G 0 0 0 
MUT3A T8C 0 0 1 
MUT3B T8A 0 0 0 
* By conventional drug susceptibility testing using the Bactec MGIT 960 system 
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2.5 DISCUSSION 
This study reports the accuracy of the Genotype MTBDRplus assay for diagnosing 
MDR-TB in new and previously treated PTB patients in Cameroon. Our analysis 
showed that based on 49 MDR-TB cases, the Genotype MTBDRplus assay had a 
sensitivity and specificity of 94% and 100%, respectively. Such high sensitivity and 
specificity values make the Genotype MTBDRplus very suitable for use to diagnose 
MTB-DR in Cameroon. The specificity and sensitivity values reported in our study are 
similar to those reported in the two systematic reviews of the Genotype MTBDRplus 
(7,8). Our participant recruitment strategy led to both a high number of positive Mtb 
cultures and MDR-TB patients (22%; 49/225). This proportion of MDR-TB patients is 
higher than the population estimate of 2.2% (460/20882) among newly diagnosed TB 
patients and 11% (170/1575) among previously treated TB patients. However, a 
sensitivity analysis indicates that the high proportion of MDR-TB patients in our study 
does not affect the positive predictive value of the Genotype MTBDRplus in diagnosing 
MDR-TB due to the high specificity value (100%) obtained. Based on our data of 94% 
sensitivity and an estimated 630 new and previously treated cases of MDR-TB annually 
in Cameroon, the Genotype MTBDRplus assay would fail annually to diagnose 32 
cases. These misdiagnosed cases would compromise the goal to identify every patient 
with MDR-TB in Cameroon. However, among the 3 MDR-TB cases not diagnosed as 
resistant to RIF and INH by the Genotype MTBDRplus assay, 2 were diagnosed as 
resistant to RIF and 1 as resistant to INH. As such, even if the Genotype MTBDRplus 
assay were to misdiagnose a few MDR-TB cases, the presence of resistance to either 
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INH or RIF among these cases would be detected. Overall, our data suggests that the 
Genotype MTBDRplus assay can be used to diagnose MDR-TB in Cameroon  
The majority 44/48 (92%) of RIF-resistant isolates detected by the Genotype 
MTBDRplus assay had mutations at codon 531 41/48 (85%) and 526 (6%). These 
mutations are known to be the most prevalent RIF-resistance associated mutations (17–
19), but their frequencies vary worldwide. The frequency of codon 531 mutation in our 
study was 85% which is higher than generally reported (20). A similar high frequency of 
codon 531 mutation among RIF-resistant isolates in Cameroon was also reported (18). 
As such, the codon 531 mutation may actually be the most prevalent RIF-resistant 
associated mutation among RIF-resistant isolates in Cameroon. The relevance of a 
predominant codon 531 mutations is unclear, but could reflect on-going transmission of 
isolates carrying this mutation. RIF-resistant associated mutation at positions 516 were 
not detected in this study, but have been reported in other studies in Cameroon (18,21).  
In this study, four RIF-resistant isolates failed to hybridize with one or two of the wild 
type (WT) probes, and did not hybridize with any of the probes representing known 
mutations. These results suggest that there is either a technical problem or a new 
previously unreported mutation. The WT probes with no hybridization were mostly WT2, 
WT3, WT4 and WT8. First, Seifert and colleagues (2016) suggest that this type of result 
is likely due to failure of the mutant to hybridize with the mutation probe and is not due 
to the presence of a rare or new mutation. They concluded that in such situations, 
improved optimization of the Genotype MTBDRplus will demonstrate hybridization to the 
mutation probes (22). However, the absence of hybridization could also indicate that 
there is a mutation at positions 511 (WT2), 516 (WT3), 526 (WT4), and/or 533 (WT8). 
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Mutations at these positions have been reported, but not all mutations have been 
associated with RIF-resistance (23–26). In the current study, the four isolates that failed 
to hybridize to one or two WT probes were RIF-resistant in the MGIT DST, making it 
likely that unknown mutations associated with RIF resistance could be present. 
Unfortunately, DNA sequencing could not be done in our study to confirm or identify the 
mutations; however, since they were resistant by MGIT DST, further studies are 
warranted.  
Besides identifying resistance to RIF or INH, the Genotype MTBDRplus assay provides 
information that is necessary for patient treatment and understanding the evolution of 
drug resistance. Mycobacterial isolates with the KatG codon 315 mutation have reduced 
ability to activate INH, but the isolate still has catalase and peroxidase activities. As 
such, isolates with this mutation can persist and be transmitted without any negative 
selection (27). Administration of a high-dose of INH (900mg) per day to patients 
harboring isolates with the inhA promoter mutations, might lead to better treatment 
outcome (2,28–30). Isolates with inhA promoter are also resistant to the anti-TB drug 
Ethionamide (ETH). As such, use of ETH will not be beneficial to the patient (31). A 
recent study suggests that routine evaluation of the frequency of the inhA promoter 
mutation can help predict progression to more severe forms of drug resistance. The 
authors of the study observed an increase in the frequency of inhA promoter mutations 
as isolates progressed to more severe forms of drug resistance, from MDR-TB, to pre-
extremely drug resistant TB (pre-XDR-TB) and XDR-TB (30,32).  
At present, the WHO recommends that the Genotype MTBDRplus assay be used 
directly on specimen without culturing if the specimen is smear positive and on Mtb 
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isolates obtained after culture (33). However, among smear positive specimens, a 
recent study showed that the Genotype MTBDRplus assay will perform best if 
specimens were graded ≥AFB2+ (34). In our study, 71% (192/270) of samples were 
≥AFB2+. Gauthier and colleagues (2014) have proposed a diagnostic algorithm where 
the Genotype MTBDRplus assay should be used directly on ≥AFB2+ specimens (35), 
which is appealing because it helps accelerate diagnosis of drug resistance. In reality, a 
significant proportion of patients will be <AFB2+ and will not be eligible for direct testing 
according to the algorithm proposed by Gauthier and colleagues (2014). In our study, 
we had 29% (78/270) of such patients. As such, use of the Genotype MTBDRplus 
assay for direct testing might not be adequate. Furthermore, most laboratories are now 
equipped with the GeneXpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) (11), that  
performs better than the MTBDRplus for direct testing of clinical specimens (36). 
However, the Genotype MTBDRplus assay offers great benefit when used on cultured 
isolates. First, results are available within 48hrs in contrast to the 7 days to weeks with 
culture-based DST. Secondly, the Genotype MTBDRplus assay is not affected by the 
presence of contamination with bacteria, fungi or non-tuberculosis mycobacteria as are 
most cultured-based DST systems (37,38). In our study, 29% (70/239) of the cultures 
were contaminated and had to be decontaminated and re-cultured before DST could be 
done.  Among the 70 repeats, we were successful in obtaining pure cultures in only 57 
cultures; whereas the other 13 remained contaminated and culture-based DST could 
not be performed. The presence of contaminants increases laboratory processing and 
reporting times that could be avoided if the Genotype MTBDRplus assay is used.  
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2.6 CONCLUSIONS 
This study showed that the Genotype MTBDRplus assay has good accuracy for 
detecting resistance to RIF, INH and MDR-TB, showing it would be useful for the 
diagnosis of MDR-TB in Cameroon. At present, there are 3 functional TB reference 
laboratories in Cameroon with culture and molecular-based capacity to diagnose drug-
resistant TB. Each laboratory serves health facilities in 3 to 4 regions of the country. The 
need to transport samples from health facilities to these reference laboratories, 
increases the turnaround time for obtaining results and the risk of having contaminated 
cultures. The Genotype MTBDRplus could be included in the diagnostic algorithm of 
MDR-TB and be used post-culture. Primarily, the Genotype MTBDRplus assay could be 
used to perform DST of Mtb positive-cultures especially for cultures containing 
contaminants for which culture based DST will be delayed. Additionally, the Genotype 
MTBDRplus assay could be used as a complementary test to confirm RIF and INH DST 
results obtained using the culture-based method. Lastly, the Genotype MTBDRplus 
assay can be used for epidemiological surveys to rapidly assess the type RIF and INH 
mutations present.  
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2.9 Tables and legends 
Table 1: Demographic characteristic of 270 eligible participants 
All Study 
participants 
N=270 (%) 
New 
PTB 
patients 
N= 79 
(%) 
Previously 
treated PTB 
patients (N= 
169) 
Patients with 
unknown 
PTB history 
(N=22) 
+P-
value 
Variables    
Age (y);  
mean SD 37.7 +13.4 
36.6 + 
14 38.0 + 13.5 39.1 + 10.7 
0.271 
Gender  0.667 
Male 179 (66) 50 (63) 113 (67) 16 (73)  
Female 91 (34) 29 (37) 56 (33) 6 (27)  
Cities <0.0001 
Bamenda 14 (5) 5 (6.3) 9 (5.3) 0 (0)  
Douala 133 (49) 65 (82.3 47 (27.8) 21 (95.5)  
Yaounde 123 (46) 9 (11.4) 113 (66.9 1 (4.5)  
HIV status 0.0008 
Positive 63 (23) 13 (16.5) 50 (29.6) 0 (0)  
Negative 140 (52) 40 (50.6) 96 (56.8) 4 (18.2)  
Unknown 67 (25) 26 (32.9) 23 (13.6) 18 (81.8)  
Smear Status 0.0012 
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Smear negative 44 (16) 5 (6.3) 38 (22.5) 1 (4.5)  
Smear positive 226 (84) 74 (93.7) 131 (77.5) 21 (95.5)  
Grading of 
positive smears     
 
Smear positive 
(AFB Scanty) 17 (6) 5 (6.8) 10 (7.6) 2 (9.1) 
 
Smear positive 
(AFB 1+) 17 (6) 6 (8.1) 8 (6.1) 3 (13.6) 
 
Smear positive 
(AFB 2+) 46 (7) 22 (29.7) 22 (16.8) 2 (9.1) 
 
Smear positive 
(AFB 3+) 146 (54) 41 (55.4) 91 (69.5) 14 (63.6) 
 
Phenotypic DST 
results    
<0.0001 
Susceptible 152 (56) 53 (67.1) 82 (48.5) 17 (77.3)  
Mono-drug 
resistant 20 (7) 7 (8.9 11 (6.5) 2 (9.1) 
 
Polydrug 
resistant 5 (2) 2 (2.5) 2 (1.2) 1 (4.5) 
 
MDR 49 (18) 7 (8.9) 42 (24.9) 0 (0)  
*None  44 (16) 10 (12.7) 32 (18.9) 2 (9.1)  
Abbreviations: SD: Standard deviation; PTB: Pulmonary Tuberculosis; AFB: Acid-
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Fast-Bacilli; DST: Drug susceptibility testing: MDR: Multidrug resistant (Resistant to 
Rifampicin (RIF) and Isoniazid (INH). 
+ The p-value was obtained from comparison between new and previously treated TB 
patients individuals  
*None implies no growth of Mycobacterium tuberculosis complex bacilli observed  
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3.1 ABSTRACT  
Mutations that enable Mycobacterium tuberculosis (Mtb) to be resistant to Rifampicin 
(RIF) are located within the rpoB gene region from codons 507 to 534. However, not 
every mutation in this region is associated with  resistance to RIF. The WHO-endorsed 
the Genotype MTBDRplus assay recommends that an Mtb isolate be assumed resistant 
to RIF solely on the basis of absence of hybridization to one or more wildtype probe on 
the assay strip. This recommendation suggests that an Mtb isolate with any mutation in 
the rpoB gene region from codon 507 to 534 should be assumed resistant to Rifampicin. 
Here, we screened 275 Mtb isolates with the Genotype MTBDRplus assay and 
identified 6% of Mtb isolates that fulfilled this recommendation. Sequencing of these Mtb 
isolates revealed that impaired hybridization to WT probes was due to the presence 
‘disputed’ RIF mutations i.e. mutations that are sometimes associated with RIF 
resistance but not always. Mtb isolates bearing these ‘disputed’ RIF mutations may be 
responsible for causing resistance to RIF and have been associated with adverse 
treatment outcome in both naïve and previously treated TB patients. Thus, the 
recommendation of the Genotype MTBDRplus assay to assume resistance based solely 
on absence of hybridization to WT probe allows the identification of clinically important 
RIF-resistant Mtb isolates. This recommendation results in accurate and rapid diagnosis 
of RIF-resistant TB by the Genotype assay.  
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3.2 INTRODUCTION 
The line-probe assay, Genotype MTBDRplus® version 2.0 (Hain Lifescience 
GmbH, Nehren, Germany) enables rapid and accurate detection of Mycobacterium 
tuberculosis (Mtb) and resistance to the anti-tuberculosis drugs, rifampicin (RIF) and 
Isoniazid (INH)(1–4). This assay is currently endorsed by the World Health Organization 
(WHO) and routinely used in TB endemic countries to diagnose and confirm resistance 
to RIF and INH (5–8).  
The Genotype MTBDRplus assay detects resistance to RIF and INH by detecting 
mutations in gene regions associated with resistance to RIF and INH. The detection of 
mutations involves a series of steps. First, DNA is extracted from Mtb. Secondly, the 
region of the gene associated with either resistance to RIF or INH is amplified by 
multiplex PCR using biotinylated primers. Next, the PCR products are allowed to 
hybridize to specific oligonucleotide probes immobilized on a nitrocellulose membrane 
strip. Lastly, streptavidin-conjugated alkaline phosphatase is added and the hybridized 
probes are revealed by the appearance of a dark color precipitate on the strip (9). For 
the detection of mutations associated with resistance to RIF, the strip contains 8 wild 
type (WT) probes that hybridize Mtb DNA from codons 507 to 534 of the rpoB gene and 
4 mutation probes that hybridize DNA that contains specific mutations at positions: 516 
(D516V), 526 (H526Y, H525D) and 531 (S531L). Likewise, for the detection of 
mutations associated with resistance to INH, the strip contains probes that hybridized 
DNA at codon 315 of the KatG gene and positions -1 to -22 on the inhA promoter 
region. Mutation probes associated with INH resistance, bind DNA with mutations at 
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position 315 of the KatG gene and at positions 8, 15 and 16 of the inhA promoter region 
(1,9).   
According to the Genotype MTBDRplus assay, an Mtb isolate could be classified 
as resistant to RIF and/or INH based on two alternative interpretations. The first 
interpretation recommends that if an isolate fails to hybridize to one or two of the WT 
probes on the strip but hybridizes to a mutation probe, the isolate is resistant to the drug 
(9). In such a case, a mutation is present and the mutation is known to be associated 
with resistance to the drug. However, the second interpretation recommends that if an 
isolate fails to hybridize to one or two of the WT probes and does not hybridize to any of 
the mutation probes, the specimen is resistant to the drug (9). In the second 
interpretation, lack of WT hybridization shows a mutation is present but makes the 
assumption that the Mtb isolate is resistant without identifying the mutation.  Since not 
all mutations confer drug-resistance, it is not clear if the assumption is correct.  For 
example, several mutations have been detected from codons 507 to 534 of the rpoB 
gene of Mtb (10), and some of these mutations could be silent mutations (11,12)  or 
missense mutations with no or unclear association with resistance to RIF (13,14). As 
such, it is important to know what type of mutation is present in order to determine if the 
Mtb isolate is resistant. 
In this study, we sought to evaluate the frequency of Mtb isolates that do not 
hybridize to rpoB WT probes and mutations probes on the Genotype MTBDRplus strip; 
and if impaired hybridization to WT probes is due to mutation associated with resistance 
to RIF or not.  
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3.3 MATERIALS AND METHODS 
Mycobacterium tuberculosis isolates. Two sets of Mtb isolates were used in 
this study. The first set of 225 isolates was from a recent study that sought to evaluate 
the accuracy of the Genotype MTBDRplus assay in diagnosing drug-resistant TB in 
Cameroonian TB patients. A detailed description of this study and findings were 
submitted for publication elsewhere (Dissertation Chapter 2). The second set of 50 Mtb 
isolates was obtained from the Mycobacteriology Unit at Centre Pasteur du Cameroon 
(Mycobact/CPC). Mycobact/CPC routinely archives drug-resistant Mtb isolates cultured 
from clinical specimen. Following a review of the laboratory records of Mycobact/CPC, 
the 50 Mtb isolates diagnosed as drug-resistant to RIF and/or INH by either the 
GeneXpert MTB/RIF assay® (Cepheid, Sunnyvale, CA, USA) or the automated 
BACTEC MGIT 960 system® (Becton Dickinson, Franklin Lakes, NJ) or by both 
systems between January 2015 and February 2016 were included in this study. Every 
Mtb isolate included in the study was isolated from a different patient.   
Genotype MTBDRplus assay. For the first set of 225 Mtb isolates, the 
previously obtained MTBDRplus results were reviewed and isolates that failed to 
hybridized to rpoB wild type (WT) and mutation probes on the Genotype MTBDRplus 
test strip were selected. The second set of samples were screened using the genotype 
MTBDRplus according to the manufacturer’s instructions (9). As with the first set of 
samples, Mtb specimens that failed to hybridized to one or more of the rpoB wild type 
(WT) probes and the mutation probe on the Genotype MTBDRplus strip were selected. 
The Genotype MTBDRplus assay was repeated for all Mtb isolates with this pattern of 
hybridization in order to confirm the results.   
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Determination of Minimum Inhibitory Concentration (MIC). MICs were only 
determined for the selected Mtb isolates with the Genotype MTBDRplus rpoB 
hybridization pattern (no hybridization to WT probes or mutation probes). 
MICs were determined using the Bactec MGIT 960 system using the standard 
drug susceptibility testing protocol provided by the manufacturer. The drug 
concentrations tested for RIF included 0.125, 0.25, 0.5, 1, 2, 4, and 8µg/ml and INH 
concentrations of 0.1, 0.2, 0.4, and 0.8 µg/ml. Not all isolates were cultured with all drug 
concentrations. Based on the MGIT 960 DST results performed at critical 
concentrations of 1 μg/ml, RIF-resistant isolates were tested with concentrations of 1, 2, 
4, and 8µg/ml and RIF-susceptible isolates were tested with concentrations of 0.125, 
0.25, 0.5, and 1 μg/ml.   
MIC values reported here as ‘>’ (e.g. > 8 µg/ml) indicates that the Growth Unit 
(GU) of the drug-containing culture tube with 8 µg/ml was >100 when the 1:100-diluted 
drug-free control tube had reached a GU of 400. MIC values reported here as ‘<’ (< e.g. 
0.25 µg/ml) indicates that the GU of the drug-containing culture tube with 0.25 µg/ml 
was < 100 when the 1:100-diluted drug-free control tube had reached a GU of 400. 
DNA extraction, PCR, and sequencing. The target Mtb isolates were grown in 
MGIT tubes using the Bactec MGIT 960 system. Following growth, the Mtb isolates 
were harvested and heat killed by boiling at 95°C for 20 min in nuclease free water to 
release DNA. Extracted DNA was used for PCR. The PCR primers and amplification 
conditions used to amplify the rpoB gene were as previously described (17). All PCR 
products were outsourced for sequencing (Genewiz, UK). Both primers used for 
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amplification and additional internal primers were used for sequencing as previously 
reported (17).  
The Array Studio Suit version 9.0 software ( Omicsoft Corporation, Weston 
Parkway, USA) on windows system was used  to analyse the sequences. The . The 
OSA4 aligner was used to align the sample sequences to the reference rpoB gene 
sequence of Mtb H37Rv. After alignment, the summarize variant data module was used 
to generate a mutation report.  
 
Ethical approval  
This study was reviewed and approved by the Institutional Review Board of the 
University of Hawaii (CHS #22381), USA, Centre Pasteur of Cameroon, the National 
Ethical Committee of Cameroon and the technical committee of the Ministry of Public 
Health, Cameroon.  
3.4 RESULTS  
 Identification of target samples. Figure 1 provides a detailed description of the 
Mtb isolates used in this study. A total of 275 Mtb isolates with known MGIT 960 drug 
susceptibility testing results and/or GeneXpert MTB/RIF results were screened by the 
Genotype MTBDRplus assay. Among the 275 samples, 16 (6%) Mtb isolates did not 
hybridize to one or more rpoB WT and mutation probes. Repeated screening of these 
samples with the Genotype MTBDRplus assay further confirmed the results. Of the 16 
Mtb isolates, 3 were resistant by GeneXpert MTB/RIF, but susceptible by MGIT 960; 
whereas, 13 were resistant by both assays. 
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Sequencing, probe hybridization and minimum inhibitory concentration. To 
determine if a mutation was present and what type of mutation it was, the 81bp 
Rifampicin Resistance Determining Region (RRDR) of the rpoB gene was sequenced. 
Table 1 shows the mutations detected by sequencing of the 16 isolates. Mutations in 
the RRDR were detected in all isolates.  
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Interestingly, as summarize in Table 2, all of the mutations detected had been 
reported previously to be ‘disputed’ rifampicin-resistant mutations (14,18,19). These 
mutations are called ‘disputed’ RIF-resistant mutations because not all isolates bearing 
these mutations have a RIF-resistant phenotype when testing is done using the 
standard phenotypic assay MGIT 960 DST system. For example, isolate S4 and S6 
were both detected to be RIF-resistant by GeneXpert and Genotype MTBDRplus assay. 
In the Genotype MTBDRplus assay, both isolates failed to hybridize to WT7. However, 
sequencing of both isolates identified the same mutation at position 526 that led to a 
change in amino acid from His to Leu (His526Leu). Phenotypic testing by the MGIT 960 
DST assay classified S4 as RIF-susceptible and S6 as RIF-resistant. MIC results of S6 
revealed the isolate had only a low level of RIF-resistance (< 4µg/ml).  
Except S4, S7 and S16, all other isolates in Table 1 were associated with a high 
level of RIF resistance (MIC > 8µg/ml). Thus, making the assumption that isolates that 
failed to hybridize with the WT probe were resistant to RIF appears to be a valid 
assumption. 
Only one discrepancy was found between the two genotyping assays. Sample 
S12 was detected as RIF-susceptible by the Genotype MTBDRplus as it hybridized to 
all WT probes and did not hybridize to a mutation probe. However, the isolate was 
detected as RIF-resistant by GeneXpert assay and sequencing revealed the presence 
of a disputed mutation Leu533Pro (Table 1).  
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3.5 DISCUSSION 
 Among our collection of 275 Mtb isolates, 16/275 (6%) of these isolates 
did not hybridize to the rpoB WT and mutant probes on the Genotype MTBDRplus strip 
assay. The frequency of isolates with such a hybridization pattern was lower than that 
reported in other published studies in other countries  (>12%) (20,21). Interestingly, 
sequencing revealed that impaired hybridization to WT probes in these isolates was due 
to the presence ‘disputed’ RIF mutations. As earlier mentioned, isolates bearing these 
mutations can occasionally be detected as RIF-susceptible with the standard MGIT 960 
DST assay (18). Disputed mutations are usually rare and assume to make up about 
14% of all rpoB mutations (14). These disputed mutations can frequently cause 
important RIF resistance among patients both naïve and previously treated TB patients 
(13,18,19). As such, assuming resistance based solely on the absence of WT probe 
hybridization significantly contributes to the detection of RIF resistant Mtb isolates that 
could be missed by the conventional culture-based drug susceptibility testing.  
At present, WHO recommends the molecular-based test GeneXpert MTB/RIF® 
as the initial diagnostic test in patients at risk of having drug-resistant Mtb(22). 
Considering the GeneXpert works on the same principle as the Genotype assay, by 
extrapolation, this test will detect patients with disputed RIF mutations as resistant to 
RIF(18). Once such a patient is diagnosed, the patient will immediately be placed on 
treatment for multidrug resistant TB. However follow up phenotype-based testing is 
required during the course of treatment and it will identify the bacteria as RIF-
susceptible. This discord in test results might raise concerns on the reliability of the 
GeneXpert MTB/RIF test and affect its use. 
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The inability of the MGIT 960 DST assay to accurately classify all isolates with 
RIF-disputed mutations as resistant could be due to the critical concentration of 1µg/ml 
RIF used in this assay. Some authors have suggested that this critical concentrations is 
set too high and should be revised to 0.0625 µg/ml (23) or 0.125 µg/ml (24). As 
observed with the MIC of the isolates in our study and those of other published studies 
(13,18), if this critical concentration is revised to 0.625-0.125 ug/ml, most and if not all of 
these isolates with RIF-disputed mutations would become classified as resistant by the 
MGIT 960 DST assay.  
Another interesting aspect about isolates with RIF-disputed mutations is that 
isolates with the same type of mutation have varying susceptibility to RIF. Certainly, 
there is a fitness cost associated with the acquisition of mutations in the rpoB gene 
(25,26). This gene codes for the β-subunit of the RNA polymerase that plays a key role 
in transcription. The mutation induced fitness cost might vary depending on the type and 
location of the mutation. For some mutations, the resultant fitness cost might be too 
high be so significant (26). For such mutants, the acquisition of a compensatory 
mutation may restore enzyme activity either partially or completely (27). Perhaps Mtb 
isolates that have a RIF-disputed mutation have a severe reduction in RNA polymerase 
activity and only isolates that acquire compensatory mutations have this activity 
restored. These compensatory mutations could arise either in the rpoB gene or genes 
that code other subunits of the RNA polymerase i.e., rpoC and rpoA genes as 
previously described (27) 
The strengths of this study are the large number of Mtb isolates screened and 
selection of isolates based on phenotypic and genotypic testing, namely MGIT 960 DST 
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and GeneXpert MTB/RIF, respectively. Our study also has some limitations such as the 
absence of patient treatment and outcome data. 
Drug-resistant tuberculosis is increasingly recognized as a threat to the global control of 
tuberculosis. The use of rapid molecular based test such as the Genotype MTBDRplus 
will enable the rapid identification of drug-resistant TB. In our study, we showed that the 
recommendation to classify an isolate as RIF resistant based solely on absence of 
hybridization to a WT probe allowed for the accurate identification of RIF-disputed 
isolates that could have been missed by relying on only the standard MGIT 960 DST 
assay for diagnosis. 
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3.8 APPENDIX: Tables and Figures 
Table 2. Phenotypic and mutation results of Mtb isolates classified as Rifampicin resistant by the Genotype MTBDRplus 
assay based solely on the absence of hybridization to Wildtype probes 
# Isolate Isolate ID 
MGIT 960 
DST RIF GeneXpert RIF 
βGenotype 
MTBDRplus 
WT absent 
MGIT 960 
MIC 
Results 
(µg/ml) 
rpoB Sequencing result 
Nucleotide Amino Acid 
2 S7, S16 Sensible Resistant WT 2 < 0.25 CTG511CCG Leu511Pro  
1 S1 Resistant Resistant WT 3 & 4 >8 CAA513CCA Gln513Pro 
1 S15 Resistant Resistant WT 2 & 3 >8 CAA513CCA Gln513Pro 
4 
S2*, S8 ,S9 
,S10 Resistant 
Resistant 
WT 3 & 4 >8 GAC516TAC Asp516Tyr 
3 
S11, S13, 
S14 Resistant 
Resistant 
WT 7 >8 CAC526CGC His526Arg 
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1 S4 Sensible Resistant WT 7 < 0.25 CAC526CTC His526Leu 
1 S6 Resistant Resistant WT 7 < 4 CAC526CTC His526Leu 
1 S5 Resistant Resistant WT 7 >8 CAC526AAC His526Asn 
1 S3 Resistant Resistant WT 8 >8 TCG531TGG Ser531Trp 
1 S12 Resistant Resistant None >8 CTG533CCG Leu533Pro 
* GeneXpert MTB/RIF was not performed on this clinical specimen 
β GeneXpert was performed directly on clinical specimens.  
All other test were performed on cultured Mycobacterium tuberculosis isolates 
Wild Type: WT; Rifampicin: RIF;  
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Figure 1. Flow chart of sample processing and identification of target samples.  
Bactec MGIT 960 system used for culture, phenotypic drug susceptibility testing 
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4.1 ABSTRACT:  
The ATP Binding Cassette B1 (ABCB1) transporter has critical roles in endo- and 
xenobiotic efficacy and toxicity. To understand population variability in hepatic 
transport we determined ABCB1 mRNA and protein levels in total liver lysates 
sampled from 8 pre-defined sites (n = 24, 18–69 years), and in S9 from randomly 
acquired samples (n = 87, 7 days–87 years). ABCB1 levels did not differ 
significantly throughout individual livers and showed 4.4-fold protein variation 
between subjects. Neither mRNA nor protein levels varied with sex, ethnicity, 
obesity or triglycerides in lysates or S9 (that showed the same relationships), but 
protein levels were lower in pediatric S9 (p < 0.0001), with 76% of adult ABCB1 
present at birth and predicted to mature in 5 years. Pediatric total liver lysates were 
not available. In summary, opportunistic collection for studying human hepatic 
ABCB1 is acceptable. Additionally, ABCB1 may be lower in children, indicating 
differential potential for toxicity and response to therapy in this special population. 
Keywords: development; pediatric; systemic toxicity; elderly; obesity 
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4.2 INTRODUCTION 
Interest in active transporters, such as the ATP Binding Cassette (ABC) 
proteins, has peaked in recent years because they play crucial roles in drug, 
chemical, hormone, and nutrient disposition [1]. Clinical and environmental studies 
increasingly consider the effects of transporters on therapeutic failure, drug 
resistance, and chemical toxicity. Despite this, very few published studies have 
determined transporter protein dynamics in human liver tissue samples—a critical 
site of transport action and critical mediator of systemic endo- and xenobiotic 
levels. Primarily, this is due to: (i) difficulties in obtaining human liver tissue 
samples; and (ii) technical challenges working with ABC proteins in the laboratory 
[2–7]. 
One of the important ABC transporters is ABCB1 (EC 3.6.3.44, P-glycoprotein, 
P-gp). The ABCB1 protein is present on the plasma membrane of almost all tissues 
of the human body (reviewed [8–12]). In the liver, it is expressed on the apical 
surface of hepatocytes. First characterized in the 1970s, ABCB1 is a 170 kDa 
protein composed of two sub-units, each containing six transmembrane domains, a 
large cytoplasmic domain, and a nucleotide binding domain [12]. Although ABCB1 
actions in the liver are necessary for elimination of substances from the body to 
maintain homeostasis, excessive expression (such as by induction) can also reduce 
the therapeutic effects of drugs and upset homeostatic balance of e.g., hormones 
and bile acids. An example of this is the drug-drug interaction between Rifampicin 
(an ABCB1 inducer) and Apixaban, where the therapeutic effect of Apixaban is 
decreased through greater elimination, increasing risk of stroke [13]. Conversely low 
expression or activity of ABCB1 may increase the risk of toxicity by compromising 
elimination. This is observed in the Apixaban/Ketoconazole interaction (ABCB1 
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inhibition by the latter), where there is an increase in total Apixaban exposure and 
risk of haemorrhage [13].  
We hypothesized that hepatic expression of ABCB1 would be greater in areas 
near the portal and bile circulation due to its physiological role as an efflux 
transporter. Currently, there are no published studies of differential regional 
expression of ABCB1 in the human liver. Regional differences in ABCB1 expression 
would have implications for sample collection and for differentiating between localized 
and systemic effects on drug and chemical disposition due to ABCB1 expression. In 
addition to understanding regional variability in hepatic ABCB1, we were interested 
in determining whether ABCB1 expression is associated with demographic 
parameters. Although studies associating expression with age, sex, and ethnicity 
have been common with metabolic enzymes [14–22] and have revealed critical 
insight into chemical action and toxicity, they largely do not exist for transport 
proteins. Based on similar roles as metabolic enzymes, we hypothesized that 
ABCB1 in the human liver would vary with age, sex, ethnicity, or obesity, and tested 
this in both the lysates as well as a larger cohort of 87 liver S9 fractions (7 days–87 
years). 
A greater knowledge of the spatial and demographic ABCB1 expression can 
help with understanding liver function and disease etiology, as well as systemic 
drug, chemical, and hormone effects mediated by liver transport. 
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4.3. MATERIALS AND METHODS  
All chemicals and reagents were from Sigma-Aldrich (St. Louis, MO, USA) 
unless otherwise stated. 
 Tissue Samples 
Liver S9 and lysate samples were released from the Hawaii Biorepository, with 
approval from the Institutional Review Board for Human Ethics at the University of 
Hawaii CHS15844 and the Review Ethics Board at the University of British 
Columbia H14-00092. The cohort was supplemented with samples purchased 
commercially from Cellzdirect (Durham, NC, USA), Puracyp (Carlsbad, CA, USA), 
and Xenotech (Lenexa, KS, USA). Table 1 summarizes donor demographics for 
the total liver lysates (n = 24). Table 2 summarizes the demographics of the S9 
liver samples (n = 87). Lysates were prepared from approximately 5 g of frozen 
tissue. Tissues were thawed and weighed and homogenized 1:3 weight:volume in 
0.1 M Tris-HCl containing 5 mM MgCl2 and 2 mM freshly prepared 
Phenylmethylsulfonyl fluoride. Tissues were homogenized to total lysate in 50 mL 
falcon tubes using a Tissue Tearor electrical homogenizer (Daigger Scientific, 
Vernon Hills, IL, USA). Total lysates were aliquoted and frozen at −80 until use. 
Extraction of mRNA and cDNA Preparation 
Total RNA (up to 5 µg) was extracted from human liver S9 (100 µL at 10–30 mg 
protein/mL). RNA (up to 6 µg) was also extracted from human liver lysates (50 µL 
at 4–50 mg protein/mL) using the RNeasy Mini kit according to the manufacturer’s 
instruction (Qiagen, Valencia, CA, USA). The RNA purity and concentration were 
determined by Nanodrop (ThermoFisher Scientific, Wilmington, DE, USA), then RNA 
was aliquoted stored at −80 °C until use. Only samples with 90% pure RNA or higher 
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(OD260/280 > 0.8) were used for reverse-transcription with an ABI High Capacity 
Reverse Transcription Kit (Life Technologies, Burlington, ON, Canada). 
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Table 1. Demographic information of the donors used to investigate regional ATP Binding Cassette B1 (ABCB1) 
expression in the liver. 
ID 
Number of Liver Samples Taken for 
Regional Study 
Age 
(Years) 
BMI 
(Kg/m2) 
Sex Ethnicity 
A 8 44 38.8 Male 
Hawaiian or other pacific 
Islander 
B 7 20 43.7 Male 
Hawaiian or other pacific 
Islander 
C 7 37 38.0 Male Caucasian 
D 8 48 31.6 Female Asian 
E 8 46 31.7 Female Caucasian 
F 2 57 22.7 Male Asian 
G 2 69 27.8 Male Caucasian 
H 2 62 35.5 Male Caucasian 
I 4 18 29.9 Male 
Hawaiian or other pacific 
Islander 
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J 8 52 24.5 Male Caucasian 
K 1 61 21.1 Female Japanese 
L 1 51 29.3 Male Asian 
M 1 47 20.3 Male Asian 
N 1 32 25.5 Male Caucasian 
O 1 57 33.4 Male Asian 
P 1 58 24.7 Male Asian 
Q 1 40 15.7 Female Caucasian 
R 1 43 29.9 Male Caucasian 
S 1 59 28.3 Male Asian 
T 1 53 20.9 Female Asian 
U 1 52 22.3 Male Caucasian 
V 1 56 34.4 Female Caucasian 
W 1 39 52.4 Female Asian 
X 1 64 34.7 Male Hispanic 
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Table 2. Demographic information of the liver cohort. 
Group 
Age Range 
Age  
Mean ± SD 
(years) 
n 
Ethnicity Sex Body Mass Index (BMI) 
Population 
0.018–87 
years 
44.8 
±22.5 
n = 87 
Caucasian  
Asian  
Pacific 
Islander  
African 
American 
Hispanic  
Other/unknow
n 
68% 
14% 
7% 
5% 
3% 
3% 
Female  
Male 
Unknown 
33% 
66% 
1% 
Underweight (BMI ≤ 18.9) 
Ideal weight (19–24.9) 
Overweight (25–29.9) 
Obese (30–39.9)  
Morbidly obese (≥40.1) 
Unknown/not included  
3% 
31% 
16% 
26% 
9% 
14 % 
Pediatrics  4.6 African- n = 2 Female  n = 2 Underweight (<5th n = 1 
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7 days—18 
years 
±5.4 
n = 12 
American 
Caucasian  
Pacific 
Islander 
Hispanic 
Other/unknow
n 
n = 6 
n = 1 
n = 1 
n = 2 
Male  
Unknown  
n = 9 
n = 1 
percent) 
Ideal weight (6–85th 
percent) 
Overweight (86–94th 
percent) 
Obese (>95th percent) 
Unknown/not included 
n = 3 
n = 2 
n = 2 
n = 4 
Adult  
19—64 years 
45.3  
±12.9 
n = 60 
Caucasian 
Asian 
Pacific 
Islander 
African 
American 
Hispanic 
Other/unknow
n 
n = 39 
n = 12 
n = 4 
n = 2 
n = 2 
n = 1 
Female 
Male 
n = 20 
n = 40 
Underweight (BMI ≤ 18.9) 
Ideal weight (19–24.9) 
Overweight (25–29.9) 
Obese (30–39.9) 
Morbidly obese (≥40.1) 
Unknown/not included 
n = 2 
n = 19 
n = 10 
n = 19 
n = 5 
n = 5 
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Geriatrics 
65–87 years 
74.6 
±6.7 
n = 15 
Caucasian 
Pacific 
Islander 
n = 14 
n = 1 
Female  
Male 
n = 7 
n = 8 
Underweight (BMI ≤ 18.9) 
Ideal weight (19–24.9) 
Overweight (25–29.9) 
Obese (30–39.9) 
Morbidly obese (≥40.1) 
Unknown/not included 
n = 0 
n = 5 
n = 2 
n = 2 
n = 3 
n = 3 
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SYBR Green q-RT-PCR and Primer Selection 
Primer sequences for ABCB1 were (F): 5′-CAC CCG ACT TAC AGA TGA TG-3′ and 
(R) 5′-GTT GCC ATT GAC TGA AAG AA-3′ with predicted amplicon length of 81 and can 
be retrieved from NM_000927 [23]. The primers for 18S rRNA were (F): 5′-CAC GGC 
CGG TAC AGT GAA A-3′ and (R): 5′-AGA GGA GCG AGC GAC CAA-3′, with a 
predicted amplicon length of 71 and can be retrieved from NR_003286.2 [24]. 
Real-time PCR was performed on an ABI Step-one-plus real time PCR system (Life 
Technologies) using cDNA template (2.5 ng RNA equivalent from S9 samples or 5 ng 
RNA equivalent from total liver lysates). First, the forward and reverse primers 
concentrations were optimized to give best signal-to-noise amplification and were 300 
nM for both forward and reverse primers for 18S and 300 nM forward and 500 nM 
reverse for ABCB1. Detection was with PerfeCTa SYBR Green SuperMix for IQ 
(Quanta BioSciences, Gaithersburg, MD, USA). Cycling conditions were: 1 cycle 30 s at 
95 °C, 40 cycles of 5 s at 95 °C, 15 s 60 °C, 10 s 70 °C then melt curve of 15 s 95 °C, 60 
s 60 °C, 15 s 95 °C. The threshold value detection (CT) was set in the exponential phase 
of amplification and quantified by normalization to 18S rRNA. Analysis was performed on 
StepOne™ software version 2.3 (Applied Biosystems, Foster City, CA, USA), with CT 
values converted to fold change differences using the 2−ΔΔCT method for relative 
quantitation [25]. 
Immunoblotting for Relative Expression of Protein 
For western blotting of ABCB1, SDS-page gels (7%) were used to resolve 20 µg of 
liver lysate or S9 and each sample was analyzed on at least 3 separate gels as 
previously described [19]. Primary antibody was rabbit polyclonal anti-ABCB1 (ab129450, 
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Abcam, Toronto, ON, Canada) incubated for 2 h at room temperature. Horseradish 
peroxidase conjugated donkey-anti-rabbit at 1:3000 was then incubated for 1 h at room 
temperature (Jackson Immunolabs, Westgrove, PA, USA). The membrane was 
developed for 1 min in enhanced chemiluminescence solution and detected on X-ray film 
for 60 min. Confirmation of even protein loading was by staining acrylamide gels with 
ponceau red and determining even loading. Additionally, a second variability control 
between blots run on different days was included. This second control was 20 µg of 
commercial human S9 from a pool of 200 individual livers, that was added to the left lane 
of every blot, and used to determine variability and to normalize expression. The inter-blot 
coefficient of variation (CV) of the XT200 was 14.6%, n = 9. Samples were semi-
quantified with Image J 1.48v (http://imagej.nih.gov/ij) with background subtraction. 
Total Triglyceride Liver Concentrations 
The triglyceride colorimetric assay kit (Cayman Chemical Company, MI, USA) was 
used to determine the levels of triglycerides (mg/g of liver) as per manufacturer’s 
instructions.  
Statistical Analyses 
All data sets were analyzed for normality with D’Agostino-Pearson tests. For sex or 
ethnicity (binary tests), student’s t-tests (two-tailed) were performed between groups. 
For binned continuous data (age, BMI), one way ANOVA with Tukey’s post hoc analysis 
was performed. Pediatric samples (<18 years) were not included in the BMI analysis, as 
BMI is not an appropriate measure for obesity in children. Where body weight was 
known, appropriate categories were assigned using the National Center for Health 
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Statistics weight-for-age growth charts for children: underweight, <5th percentile; ideal 
weight, 5–85th; overweight, 86–94th; obese, >95th percentile 
(http://www.cdc.gov/growthcharts [26], Table 2). Correlations between mRNA and protein 
were performed using Pearson’s or Spearman’s correlation according to the normality 
distribution. A one-phase association (not forced through zero), straight line, and 
sigmoidal fits were compared to predict development of ABCB1 protein expression from 
birth. The best fit was determined using Aikake’s informative criteria (AIC), F-tests, sum 
of squares and residual analysis. All statistical analyses were performed using Prism 
5.0 for Mac OsX (Graph Pad Prism, San Diego, CA, USA). 
4.4 RESULTS 
Expression ABCB1 mRNA and Protein in Hepatic Lysates: Regional and 
Demographic Associations 
Transporter mRNA expression was determined in a cohort of 24 individual livers 
using multiple pieces from each liver obtained from 8 distinct regions (not all samples were 
available from all individuals, Figure 1a). There were no significant differences in ABCB1 
mRNA regional expression (Figure 1b). The mean CT values (± SD) for 18S and ABCB1 
were 13.3 ± 2.2 and 32.6 ± 2.8, respectively. The ABCB1 mRNA levels had an average 
30-fold variability in mRNA levels. Similarly, there were no significant differences in 
protein expression of ABCB1 throughout the liver (Figure 1c). The highest level of 
protein and greatest range of ABCB1 expression was detected in the samples taken 
adjacent to bile ducts. The levels of ABCB1 mRNA and protein did not correlate (Figure 
1d), indicating that ABCB1 expression is not purely transcriptional. 
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Hepatic ABCB1 protein levels within the regional expression lysate cohort ranged 
from 3.4 ± 0.7 to 6.7 ± 3.0 area: density units (mean ± SD, Figure 1f). Lysates average 
five times more ABCB1 protein than S9 fractions. Intra-individual variability in hepatic 
ABCB1 protein expression, taken from eight different sites in the same liver, ranged from 
1.2- to 4-fold with a mean value of 2.5 ± 0.9-fold (Figure 1f). In these total liver lysates, 
there was no significant correlation of ABCB1 protein with age, BMI, sex, or ethnicity 
(Figure 2a–d). However, for ethnicity it should be noted that statistical comparisons 
essentially compare Caucasians and Asians due to the small sample size for Hispanics 
and Hawaiians. 
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Figure 1. Cont. 
 
Figure 1. Expression of ABCB1 within different human liver regions. (a) Diagram of 
the different regions where samples taken within the same liver; (b) The mRNA 
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expression of ABCB1 was determined within different regions of 14 different 
livers; (c) Protein expression of ABCB1 within different human liver regions: 
(distal large lobe n = 8; distal small lobe n = 6), medial large lobe n = 7; medial 
small lobe  
n = 6, central large lobe n = 10, central small lobe n = 5, APC = adjacent to portal 
circulation n = 6 and ABD = adjacent to bile duct N = 11); (d) Correlation between 
mRNA expression and protein expression for ABCB1, with 95 % confidence 
intervals (dotted line), and data analyzed by Spearman’s correlation; (e) ABCB1 
mRNA expression (line = means) within the livers of 10 individuals; (f) The 
ABCB1 protein expression showing intra-individual variability of protein 
expression (8 regions for A, D, E, J; 7 regions for B and C; 4 regions for I and 2 
regions for F, G and H). 
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Figure 2: The protein expression of ABCB1 in a cohort of 24 liver lysates. The 
ABCB1 protein was detected by Western blotting and normalized to the ABCB1 
levels detected in a pooled S9 liver sample (Xenotech, n = 200 individuals); (a) 
correlation between age and ABCB1 protein expression with dotted lines 95% 
confidence intervals; (b) Expression of ABCB1 protein compared with BMI; (c) The 
expression of ABCB1 proteins compared to sex; (d) Differences between 
ethnicity and ABCB1 protein expression. 
Similarly, for triglycerides mean levels were 15.4 ± 1.2 mg/g of liver (mean ± SD). 
There were no regional differences in triglyceride levels (Figure 3a), but triglycerides 
varied significantly between individuals (Tukey p < 0.0001, Figure 3b). There was no 
correlation between hepatic triglyceride levels and age, BMI, sex, or ethnicity (Figure 
3c–f). Triglyceride levels did not correlate with ABCB1 mRNA (r = −0.004, p = 0.98) or 
protein (r = −0.23, p = 0.30). 
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Figure 3: Triglyceride levels in human liver lysates. (a) The regional expression 
of hepatic triglyceride levels: 1 & 4 distal, 2 & 5 medial, 3 & 6 central, APC = 
adjacent to portal circulation and ABD = adjacent to bile duct, see Figure 1a for 
detailed liver regions; (b) The inter- and intra-individual expression of 
triglycerides levels. The correlation of triglyceride levels with (c) age and (d) 
BMI. The relationship between triglyceride levels and (e) sex and (f) ethnicity. 
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Expression of ABCB1 in Hepatic S9: Demographic and Ontogenetic Associations 
Because we only had adult total liver lysates, to provide further insight into the 
ontogeny of ABCB1 we analyzed a cohort of liver S9 where pediatric, adult, and elderly 
samples were available (Table 2). The ABCB1 mRNA (n = 79) was detectable from birth, 
and a significant negative correlation with age was observed (Pearson r = −0.3, p = 
0.02), although the correlation coefficient suggested that this was only a moderate 
association, with 8% of the change in mRNA expression being attributed to age as a 
covariate (Figure 4a). When grouped into categories, the elderly (>65 years, mean ΔCT ± 
SEM of 22.7 ± 0.4) had lower ABCB1 mRNA levels than adults (mean ΔCT ± SEM of 
21.6 ± 0.2, Figure 4b). Although not statistically significant, this 2-fold difference in gene 
expression is driving the negative association. Exactly the same as in the case of the 
total lysates, there were no significant differences observed for BMI, ethnicity, or sex in 
ABCB1 mRNA expression levels in S9 (Figure 4c–e). Pediatric samples (<18 years) 
were not included in the BMI analysis, as BMI is not an appropriate measure for obesity 
in children; rather, percentile-weight-for-age (National Center for Health Statistics) was 
used. 
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Figure 4. The mRNA expression of ABCB1 in a cohort of 80 liver samples 
Gene expression was measured using SYBRGreen detection and ABCB1 gene 
expression was normalized to 18S to give ΔCT value. (a) Line graph shows 
linear regression with 95% confidence intervals, (dotted line), of age compared 
to gene expression. Data analyzed by Pearson’s correlation (* p < 0.05); (b) Dot 
blot compare gene expression levels with age grouped into pediatric (≤18 
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years), adult (19–64 years), and geriatric (≥65 years) and data showing mean 
(horizontal line). The mRNA expression was also compared to (c) obesity, 
measured by BMI, (d) Ethnicity, and (e) Sex. 
Subsequently, we performed the same analysis for ABCB1 protein levels (n = 87). A 
representative Western blot image for ABCB1 detection is presented in Figure 5a. There 
was a 2.9 ± 0.32 -fold variability for ABCB1 protein levels in the population sampled 
ranging from 0.44 to 1.26 area:density units. Again, the same relationships were 
observed in S9 as total liver lysates, with no significant differences in ABCB1 protein 
expression observed for obesity (BMI, range 15.8–57.6) ethnicity, or sex (Figure 5d–f). 
However, different to total lysates where no pediatric samples were available, children 
have lower ABCB1 than adults. The ABCB1 protein was detected from birth and 
increased with age following a mono-exponential rise-to-plateau relationship with best fit 
(F-test; and fit parameters of AICc, 15.56, Sum of Squares 0.77, Figure 5b). This model 
predicts protein levels are at 76% of adult levels at birth and reach adult levels (±10%) 
by 5 years of age. Using categorical data, children had a significantly lower ABCB1 
protein levels than adults (p < 0.001, Figure 5c). Although the elderly population had a 
trend towards lower ABCB1 expression than adults, this was not significantly different.  
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Figure 5. Protein expression of ABCB1 in a liver cohort. The ABCB1 protein 
was detected by Western blotting and normalized to the ABCB1 levels detected 
in a pooled S9 liver sample (Xenotech, n = 200 individuals). (a) Example of 
Western blot of 6 individuals with 20 µg liver S9 loaded compared with pooled S9 
sample, ABCB1 = recombinant ABCB1 expressed in baculosome (5 µg), and blank 
= baculosome with no expression (5 µg); (b) Relationship between age and 
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ABCB1 protein expression with a one-phase association, with 95% confidence 
intervals (dotted line); (c) Protein expression compared to individuals grouped by 
age and analyzed by ANOVA (p < 0.0001) and ABCB1 expression in pediatrics 
was significantly lower compared to adults and geriatrics (Tukey’s multiple 
comparison test, *** p < 0.0001, * p < 0.05); (d): Expression of ABCB1 protein in 
obese individuals, measured by BMI; (e): Differences between ethnicity and 
ABCB1 protein expression; (f): The expression of ABCB1 proteins compared to 
sex. 
 
4.5 DISCUSSION 
One of the key findings in this study was that ABCB1 protein expression does not differ 
significantly in different liver regions; this indicates that random collection of liver tissue 
is appropriate for studying ABCB1 ex vivo. The caveat to this finding is that in 
standardizing our assays on a per milligram of protein basis, we have assumed that 
there are equal numbers of hepatocytes per milligram of tissue in each of the 8 liver 
regions sampled. Although tissues did not differ visually in any way, but we did not 
confirm cell types histologically. No significant differences were associated with 
ethnicity, sex, or obesity (measured by both BMI and liver fat levels).  
The BMI parameter is frequently used as a measure for obesity; however, this can be 
flawed [27,28], and many healthy individuals have high BMI but would have low internal 
fats (for example certain athletes) [29]. We therefore additionally evaluated liver 
triglyceride levels to understand if the pathological manifestation of obesity (liver fat) 
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could alter ABCB1 expression. Although the ABCB1 transporter is known to be involved 
in endogenous movement of cholesterol, phospholipids, and sphingolipids, and 
therefore plays a role in lipid homeostasis [30], neither triglyceride levels nor BMI were 
related to differences in ABCB1, a novel finding. 
Finally, because we did not have pediatric or significant numbers of elderly liver 
lysates, we used S9 to determine ontogenetic differences in ABCB1. Children (≤18) 
have significantly lower and more variable expression of hepatic ABCB1 protein than 
adults, with ~76% of adult ABCB1 protein levels present at birth, reaching full maturity by 
five years of age. The strength of the data presented is that in every other category 
tested, S9 results were reflective of liver lysates, albeit with lower absolute levels of 
mRNA and protein present. In addition, all of the S9 samples were treated the same way 
i.e., similarly depleted of membranes, so the relative variability of the ABCB1 proteins 
should be preserved, even though absolute levels are not.  
Relatively few studies of pediatric ABCB1 and ontogeny exist. Miki et al., 2005, 
reported no differences in hepatic ABCB1 mRNA but significant decreases in mRNA 
expression in the lungs of the elderly [4]. Moreover, several studies have investigated 
the ontogeny of intestinal ABCB1 in humans [5,31–33]. Immunohistochemistry 
techniques have demonstrated that the transporter is differentially expressed in children 
under the age of three: ABCB1 is present on both the apical and basolateral surfaces of 
enterocytes, while after three the protein is only detected apically [31]. Recently, lower 
neonatal intestine mRNA levels have been reported that reach adult levels in early 
childhood [5]. However, subsequent tests of hepatic and intestinal proteins by the same 
authors using LCMS showed stable expression of ABCB1 from fetus to adult, albeit in 
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fewer samples than presented here [33]. These studies suggest that organ-specific and 
ontogenetic regulation of ABCB1 protein is likely, albeit with some disagreement in the 
literature.  
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4.6 CONCLUSIONS 
In summary, investigators who collect human liver samples opportunistically, as well 
as those who collect uniformly from a single site, likely have a cohort representative of 
population variability in ABCB1 that can be accurate for extrapolation. Additionally, 
children under five express less hepatic ABCB1 than the general population, which could 
cause xeno- and endobiotic toxicity including altered responses to therapy, but this 
requires confirmation in a larger study, preferably using total liver lysates. Better 
understanding of the natural expression patterns of ABCB1 in the human liver can 
assist in translating work from human tissues into understanding of the mechanisms of 
drug and chemical efficacy, toxicity, and resistance. 
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CHAPTER 5 
5.1 DISCUSSION  
The availability of new anti-TB drugs in the 1950s and 60s (1) heralded an age of 
great optimism in the control of TB (2). Immediately after these drugs were introduced 
into clinical practice, the incidence of TB began to decline (3). Countries such as the 
United States reported a yearly decline of 6% in TB incidence (2). Unfortunately, by the 
late 1980s, this declining trend reversed and the incidence of TB once again began to 
rise (4,5). The growing worldwide TB incidence became so alarming that in 1993, the 
WHO declared TB a ‘global emergency’ (3). The resurgence of TB in the 1980s and 90s 
was due to the HIV epidemic, the emergence drug-resistant Mycobacterium 
tuberculosis (Mtb), increased immigration of people from TB endemic countries, lack of 
an effective global response to TB control, and the neglect of TB as a global priority (6). 
In response, to the public health threat posed by TB in the 1990s, the WHO called for 
the adoption of a series of recommendations. The main recommendations were the 
universal adoption of the current short-course (6 months) treatment regimen, supervised 
pharmacotherapy through the Directly Observed Treatment Short-course program, and 
the establishment of effective TB control programs in all TB endemic countries (3). 
Since then, TB incidence has been declining with some reports suggesting an average 
worldwide drop of 1.5% per year since 2000 (7). This new declining TB trend has once 
more nurtured new hope of eliminating TB. This renewed hope has attracted a lot of 
interest and there is now a push to put an end to the global TB epidemic as exemplified 
in the recently published WHO End TB strategy (8). The End TB strategy aims to 
reduce TB deaths by 95% and to cut new cases by 90% between 2015 and 2035 (8).  
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A central tenet of the End TB strategy is to treat every TB patient with the 6-
month short course regimen composed of Rifampicin (RIF), Isoniazid (INH), ethambutol 
(EMB) and Pyrazinamide (PZA).  Treatment of TB patients with this regimen is expected 
to lead to treatment success in all patients who adhere to the regimen (9) and minimize 
transmission of TB to other persons. Unfortunately, about 12 - 20% of TB patients fail 
treatment and another 3 – 10% relapse within two years of completing their medication 
regimen (7,10,11). In general, the successful treatment of TB patients with this standard 
6-month regimen relies on a combination of microbial and host factors. TB patients 
infected with Mtb bacilli that are resistant to the drugs are likely to fail treatment (12–16). 
Likewise, patients with low plasma anti-TB drug levels are also likely to fail treatment 
(17,18). 
This dissertation was undertaken to evaluate the accuracy of molecular based 
assays to diagnose of drug-resistant TB and to investigate P-glycoprotein as a 
determinant for low plasma concentration of Rif in TB patients. Specifically, the following 
questions were addressed 1) Does the Genotype MTBDRplus assay accurately 
distinguish RIF and INH drug-resistant from drug-susceptible Mycobacterium 
tuberculosis isolates in Cameroonian TB patients? 2) Does the recommendation to 
consider Mtb isolates that do not hybridize with the wildtype and mutation rpoB probes 
on the Genotype MTBDRplus strip as resistant, falsely diagnose resistance to RIF? 
According to the Genotype MTBDRplus assay, a Mycobacterium tuberculosis isolate 
could be classified as resistant if its DNA does not hybridize to a wild type probe and a 
mutation probe on the assay strip. This recommendation assumes that a mutation is 
present, the type of mutation is unknown and, the bacteria are resistant to RIF. 
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However, not all mutations in the rpoβ gene region assessed by the Genotype 
MTBDRplus assay are associated with resistance to RIF. 3) Does the expression of P-
glycoprotein in the liver vary extensively among individuals especially individuals of 
different ages?  
 
Does the Genotype MTBDRplus assay accurately distinguish RIF and INH drug-
resistant from drug-susceptible M. tuberculosis in Cameroonian TB patients? 
 Of the two commercially available genotype-based assays used by most 
diagnostic laboratories in TB endemic countries, only the Genotype MTBDRplus assay 
is designed to detect resistance to both RIF and INH (19,20). The other genotype-based 
assay GeneXpert MTB/RIF, only diagnoses resistance to RIF (21). However, the  
GeneXpert MTB/RIF assay is preferred and used by most laboratories as the first line 
test to screen for RIF-resistant TB among patients (22–24). This preference could be 
attributed to three main advantages of the GeneXpert MTB/RIF assay. First the 
GeneXpert assay has a faster turnaround time (2 hours). Secondly, it can be used 
directly on clinical specimen. Lastly, the diagnosis of resistance to RIF also serves as a 
good diagnostic marker for resistance to INH. As such, patients diagnosed as RIF 
resistant by the GeneXpert MTB/RIF assay are immediately placed on multidrug 
resistant TB (MDR-TB) regimen (23,24).  
Despite the excellent qualities of the GeneXpert MTB/RIF assay, it presents 
some limitations that could be resolved using the Genotype MTBDRplus assay. The 
GeneXpert MTB/RIF assay cannot diagnose resistance to INH; whereas, the Genotype 
MTBDRplus assay can (19). INH-resistant TB, that is not resistant to RIF, is common 
 138 
and treatment of such patient with the standard 6 months regimen leads to poor 
treatment outcome (25). Furthermore, resistance to INH increases the risk of developing 
resistance to other drugs (25). As such, diagnosing INH-resistant TB that is not resistant 
to RIF is important and the Genotype assay can diagnose such cases (19). Direct 
testing of clinical specimens from previously treated TB patients may lead to false- 
positive results due to the presence of residual DNA from dead Mtb bacilli (26). Use of 
cultured specimens that are recommended for the Genotype MTBDRplus assay will 
prevent false-positive TB results but increase time to availability of results by about a 
week or more. 
Our study showed that the Genotype MTBDRplus performed well in diagnosing 
RIF and INH drug resistant Mtb isolates cultured from sputum specimens from 
Cameroonian TB patients. We evaluated the Genotype MTBDRplus results to those of 
the standard method for drug susceptibility testing, Bactec MGTI 960 SIRE system. The 
Genotype assay correctly identified RIF resistance in 48/49 (sensitivity, 98% [CI, 89%-
100%]), INH resistance in 55/60 (sensitivity 92% [CI, 82%-96%]), and resistance to both 
RIF and INH (MDR-TB) 46/49 (sensitivity, 94% [CI, 83%-98%]). The specificity for the 
detection of RIF resistant and MDR-TB cases was 100% (CI, 98%-100%), while that of 
INH resistant was 99% (CI, 97% -100%). The positive predictive value (PPV) and 
negative predictive value (NPV) of the Genotype MTBDRplus assay were high for RIF 
resistance, INH resistance and MDR-TB, ranging from 97%-100%. The degree of 
agreement to the standard drug susceptibility testing assay for the diagnosis of MDR-TB 
was very good (Kappa = 0.96 [CI, 0.92-1.00]). 
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Overall, our data shows that the Genotype MTBDRplus assay can be used to 
diagnose MDR-TB in Cameroon. The National Tuberculosis Control Program of 
Cameroon (NTCP) plans to use the Genotype MTBDRplus assay for the rapid diagnosis 
of patients with drug-resistant TB. This study provides the necessary scientific evidence 
to guide the NTCP on the accuracy of this assay if used. Furthermore, we propose that 
for routine diagnoses, the Genotype MTBDRplus assay be used to perform drug 
susceptibility testing of Mtb positive-cultures especially for cultures containing 
contaminants for which culture-based drug susceptibility testing will be delayed. The 
Genotype MTBDRplus assay has a faster turnaround time of 48 hours compared to the 
2 weeks post-culture required for the standard culture-based drug susceptibility testing 
assay. Lastly, the Genotype MTBDRplus assay could be used as a rapid 
complementary test to confirm resistance to RIF detected by the GeneXpert MTB/RIF 
assay.  
 
Does the recommendation to consider Mtb isolates that do not hybridize to 
wildtype and mutation rpoB probe as resistant over-diagnose resistance to RIF? 
The Genotype MTBDRplus assay is highly accurate in diagnosing drug-resistant 
TB including resistance to RIF (27,28). The Genotype MTBDRplus assay detects 
resistance to RIF by detecting mutations from codons 507 to 534 of the rpoB of Mtb. 
Although 95% of RIF-resistant Mtb isolates have mutations within this region of the rpoB 
gene, not all mutations in this region are associated with resistance to RIF (29,30). 
However, the Genotype MTBDRplus assay recommends that an Mtb isolate be 
assumed resistant to RIF solely on the basis of absence of hybridization to one or more 
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wildtype probe on the assay strip(19,20). This recommendation suggests that an Mtb 
isolate with any mutation in the rpoB gene region from codon 507 to 534 be assumed to 
be resistant to Rif. Some of these mutations could be silent mutations (31,32)  or 
missense mutations with no or unclear association with resistance to RIF (33,34). As 
such, it is important to know what type of mutations is present to determine if the Mtb 
isolate is resistant. 
In our study, we show that only 6% (16/275) Mtb isolates fall into this category 
and have the potential for miss-classification using the Genotype MTBDRplus 
recommendation. Interestingly, sequencing of these Mtb isolates revealed that impaired 
hybridization to WT probes was due to the presence of ‘disputed’ RIF mutations. These 
mutations are referred to as ‘disputed’ because isolates bearing them may be detected 
as RIF-susceptible with the standard MGIT 960 DST assay (35). Mtb isolates bearing 
these ‘disputed’ RIF mutations may be responsible for causing resistance to RIF and 
have been associated with adverse treatment outcome in both naïve and previously 
treated TB patients (35–37). Thus, the recommendation of the Genotype MTBDRplus 
assay to assume resistance based solely on the absence of hybridization to WT probe 
is valid and allows the identification of clinically important RIF-resistant Mtb isolates. 
This recommendation leads to accurate and rapid diagnosis of RIF-resistant TB by the 
Genotype assay.  
Unfortunately, the scope of our study did not allow us to investigate why disputed 
mutations resulted in varying susceptibility to RIF by the MGIT 960 DST assay. Perhaps 
Mtb isolates that have a RIF-disputed mutation have a severe reduction in RNA 
polymerase activity and only isolates that acquire compensatory mutations have this 
 141 
polymerase activity restored. This compensatory mutation could arise either in the rpoB 
gene or genes that code other subunits of the RNA polymerase, such as the rpoC gene 
and rpoA as previously described (27). 
Does the expression of P-glycoprotein in the liver vary extensively among 
individuals, especially individuals of different ages?  
 The bactericidal effect of RIF on M. tuberculosis is concentration-dependent 
(39,40). The plasma concentration of RIF varies extensively in TB patients with some 
patients having lower than expected plasma concentrations (41–44). Low plasma 
concentration to a single drug in the multidrug treatment regimen of TB is associated 
with treatment failure and development of bacterial resistance (45). Low plasma 
concentrations of anti-TB drugs could result from several factors (46–48), but the most 
likely is variation in the rate at which the drug is cleared from the blood (48,49). For RIF, 
a drug that is largely cleared from blood by the liver and excreted in bile (50), variation 
in plasma concentration could be due to differences in the rate of biliary excretion. The 
biliary excretion of RIF is mediated by the membrane transporter, p-glycoprotein 
(51,52). As such, variation in the plasma concentration of RIF could be due to inter-
individual variability in the expression of p-glycoprotein.  
 Ideally, to investigate our study hypothesis, liver biopsies from TB patients would 
be required. Considering the challenges in obtaining such samples, we first opted to test 
if the protein levels of p-glycoprotein (p-gp) varied extensively across different age 
groups in a healthy population. A unique collection of 87 liver samples of different age 
individuals (7days – 87 years), ethnicity and gender obtained from organ donors who 
had met with accidental death were used. Contrary to our expectations, neither p-gp 
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protein nor mRNA-expression levels varied extensively between individuals. A 2.9 + 
0.32 fold variability of p-gp protein levels was observed. However, with our unique set of 
samples, results showed that p-glycoprotein is expressed from birth and increases with 
age reaching 90% of adult levels by 5 years of age. Although functionality of p-gp was 
not tested, the early and high levels of expression of p-gp in the pediatric liver are likely 
to be functional. As such, the pediatric liver is capable of mediating biliary clearance of 
drugs and biomolecules that are substrates of p-glycoprotein. The rate at which the liver 
clears RIF from blood is determined by the rate of blood flow to the liver and the ability 
of the liver to extract, and excrete RIF from the blood. The relative liver weight and 
hepatic blood flow rate per unit liver weight is higher in children than in adults (53). 
Assuming the p-gp is fully functional in the livers of children, children may demonstrate 
a higher excretion rate when given a dose/kg of RIF similar to adults. Interestingly, this 
ability of children to rapidly eliminate RIF has been observed clinically, but the 
mechanism or reason was unknown (54,55). Consequentially, in 2009, the World Health 
Organization (WHO) revised and increased the daily dosage of RIF for children from 10 
to 15mg/kg (56). Our data on p-gp protein expression levels provides a plausible 
explanation of why children, when given the same dose/kg of RIF as adults, have a 
lower plasma concentration.  
 Unfortunately, our data does not support our hypothesis that biliary clearance 
mediated by p-glycoprotein accounted for the variation in plasma concentration of RIF 
seen in TB patients. However, other transporters or metabolic enzymes involve in the 
systemic clearance of RIF may be involved. Recent evidence suggests that the uptake 
transporter SLCO1B1 could be responsible for the variation in the plasma concentration 
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of RIF. This uptake transporter is responsible for the uptake of RIF from blood into 
hepatocytes (52,57). Weiner and colleagues reported a 36% reduction in the 
bioavailability of RIF in individuals with a single nucleotide polymorphism (SNP) in the 
SLCO1B1 gene (57). Chigusta and colleagues reporting on another SNP in this uptake 
transporter, also reported a low bioavailability of RIF in a South African population (52). 
Although genetic polymorphism in the SLCO1B1 could account for the variation in 
plasma concentration of RIF; however, when adjusted for this transporter polymorphism 
other factors seemed to account for the variation of the plasma concentration of RIF 
(52,57). It is potentially possible that a polymorphism in p-glycoprotein could affect 
plasma concentration of RIF; however, it is most likely variation in plasma concentration 
in TB patients involves several factors such as poor absorption, pre-systemic and 
systemic clearance.   
Besides our focus on low plasma concentration of RIF, our study also provides 
information on the developmental changes of p-gp with age, gender and ethnicity. P-
glycoprotein is a major determinant of the pharmacokinetic, safety and efficacy of 
profiles of many drugs (58). As such, the information provided will be very useful in the 
development of drugs that are substrates of p-gp, such as HIV protease inhibitor 
saquinavir (59). Lastly, since the liver biopsies used in this study were from different 
regions of the liver, we investigated the regional expression of p-gp across the liver. Our 
data show the amount of p-gp is similar in different regions of the human livers and that 
collecting liver biopsies from any section of the liver for p-gp analysis is acceptable.  
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5.2 CONCLUSION  
Each study aim sought to address a specific research question but overall, all the 
studies improved our understanding of why patients fail treatment and provide 
measures that could be used to improve treatment outcome of TB patients. First, our 
evaluation of the Genotype MTBDRplus assay showed that this assay can accurately 
distinguish RIF and INH drug-resistant from drug-susceptible M. tuberculosis isolates in 
Cameroonian TB patients and can be used diagnose MDR-TB in Cameroon. Secondly, 
we showed that the recommendation to assume resistant to RIF solely on the basis of 
absence of hybridization to one or more wildtype probe on the Genotype MTBDRplus 
assay strip allows accurate identification of clinically important RIF-resistant Mtb 
isolates. This recommendation leads to accurate and rapid diagnosis of RIF-resistant 
TB by the Genotype assay. Finally, we showed that the expression of P-glycoprotein in 
the liver does not vary extensively and probably does not account for the variation in the 
systemic clearance of RIF. Interestingly, the detection of high levels of expression of p-
gp in the liver of children could provide a plausible explanation of why children, when 
given the same dose/kg of RIF similar as adults, have lower plasma concentrations of 
RIF.  
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